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Abstract
Spinocerebellar ataxia type-3 is a late-onset autosomal dominant progressive
neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in the MJD]
gene. The pathology of SCA3 is characterized by the presence ofnuclear inclusions
(NIs) within neurons of selectively affected brain regions. One of the contributing factors
to neuronal toxicity is the production ofpolyalanine proteins through a ribosomal -1
frameshifi within the CAG-repeat during translation. To further investigate ribosomal
frameshifting, we established a cellular mode! using three full-length MJD1 constructs
based on the cDNA of the MJDJ gene coding for various polyglutamine repeat lengths
(CAG9, CAG 100, and CAA96). We confirmed that with these constructs, -1
frameshifting occurs exclusively with the expanded-CAG repeat construct (CAG100), as
it appears to be dependent on the energy requirements necessary to unfold secondary
mRNA structures ofthe long CAG repeats. The presence oftoxic polyalanine proteins
produced by frameshifting most likely contributes to the pathogenesis ofSCA3. Through
the use of our newly established cellular mode! and Drosophila model, we also
investigated transcriptional dysregulation through impaired RNA polymerase II
(RNAPII) function. Our results show that transcriptional impairment in SCA3 appears to
be independent ofRNAPII activity alterations. In conclusion, we confirmed the
production of frameshifted polyalanine proteins in a full-length ataxin-3 cellu!ar mode!,
but require further studies to understand the mechanism of transcription dysregulation
involved in the pathogenesis of SCA3.
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Key words: Spinocerebellar ataxia type-3 (SCA3), neurodegeneration, ataxin-3, nuclear
inclusions, polyglutamine, polyalanine, frameshifting, RNA polymerase II, neurotoxicity,
triplet expansion.
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Résumé
L’ataxie spinocérébelleuse de type-3 (SCA3) est une maladie neurodegenerative
autosomique dominante observée chez des individus d’âge adulte qui est causée par une
expansion de séquences répétées de trinucleotide CAG dans le gène MJD]. La
pathologie de SCA3 est caractérisée par la présence d’inclusions nucléaires (INs) dans les
neurones des régions cérébrales distinctement affectées. Un des facteurs qui contribue à
la neurotoxicité observée est la production de protéines contenant des polyalanines qui
font suite à un changement -1 du cadre de lecture ribosomique à l’intérieur des séquences
de CAG répétées, pendant la traduction. Afin de mieux étudier ce changement, nous
avons établi un modèle cellulaire en utilisant trois constructions de MJD 1 basées sur la
séquence complète de cDNA du gène MJD] exprimant trois longueurs de répétitions de
polyglutamine (CAG9, CAG100, et CAA96). À l’aide de nos constructions, nous avons
confirmé que le changement de cadre de lecture ne se produit que lorsque la construction
de CAG longue est utilisée (CAG100); ce changement semble être relié à l’énergie
nécessaire au dépliement de structures d’ARN secondaire particulières aux longue
répétions de CAG. Il est probable que la présence des protéines contenant des
polyalanines toxiques contribue à la pathogenèse de SCA3. Aussi, en utilisant les
modèles cellulaire et de drosophile que nous avons établi, nous avons testé un mécanisme
de déregulation transcriptionelle lié à la fonction altérée de la polymérase II d’ARN
(RNAPII). Nos résultats démontrent que dans la maladie SCA3, l’altération
transcriptionelle semble être indépendante des modifications fonctionnelles de RNAPII.
En conclusion, nous avons confirmé l’implication des protéines de polyalanine dans notre
iv
modèle de la maladie, mais d’autres études seront nécessaires pour mieux comprendre la
dérégulation transcriptionelle dans la pathogénèse de SCA3.
Mots clés: ataxie spinocérébelleuse de type-3 (SCA3), neurodegeneration, ataxine-3,
inclusions nucléaires, polyglutamine, polyalanine, changement de cadre de lecture, ARN
polymérase II , neurotoxicité, expansion de triplet.
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1Chapter J: Introduction
1.1 Trinucleotide repeat expansion diseases
Trinucleotide repeat expansion diseases are due to unstable trinucleotide sequences which
are repeated several times within a stretch ofDNA (Cummings and Zoghbi, 2000). The
number ofrepeats is polymorphic in a normal population and no phenotype is observed
until their expansion reaches a pathogenic length unique to each gene (Jasinska et al.,
2003). These diseases are categorized into two subclasses depending on the location of
the repeat with respect to the gene. The first subclass, accounting for seven diseases, has
its repeats in non-coding sequences ofDNA (Jasinska et al., 2003; Di Prospero and
Fishbeck, 2005). The second subclass, consisting ofup to nine diseases, is caused by an
expansion ofa CAG trinucleotide repeat within the coding region ofthe causative gene
(Pearson et al., 2005). This group includes spinobulbar muscular atrophy (SBMA),
Huntington’s disease (HD), the spinocerebellar ataxias (SCAs) (1, 2, 3, 6, 7, 17), and
dentatorubropallidoluysian atrophy (DRPLA) (Pearson et al., 2005). Because the CAG
trinucleotide encodes the amino acid glutamine, these nine diseases are commonly
referred to as polyglutamine diseases (Table 1.1).
Trinucleotide repeats are unstable in both somatic and germ cells (Pearson et al., 2005).
The exact cause ofthe triplet expansion is unknown, but most likely invoïves one or more
ofthe following processes: formation ofunusual DNA structures and DNA slippage
during lagging-strand synthesis; aberrant repair of DNA mutagenic intermediates such as
2double-strand or single-strand breaks, or endogenous DNA damage; or, recombination
within the repeats by intrachromosomal strand annealing (Pearson et al., 2005).
Three possible mechanisms ofpathogenicity caused by triplet repeat expansions have
been identified. The first, the gain-of-function mechanism for dominantly inherited
diseases, such as in the expanded CAG repeat disorders, is based on abnormal protein
products with expanded polyglutamine tracts which lead to misfolding and novel altered
functions (La Spada and Taylor, 2003; Perutz et al., 1999). The second, the loss-of
function mechanism for recessively inherited diseases, such as in fragile X syndrome and
friedrich ataxia, is based on transcriptional interference of the affected gene leading to
reduced levels oftheir protein products (Pieretti et al., 199f; Bardoni and Mandel, 2002).
The third is also a gain-of-function mechanism for dominantly inherited diseases, but is
based on abnormal interactions at the RNA level ofthe affected gene leading to disrupted
processing and nuclear accumulation of the transcript, such as in the case ofmyotonic
dystrophy (Wang et al., 1995; Taneja et al., 1995).
3Table 1.1 Trinucleotide repeat expansion disorders. Adapted from Cummings and Zhoghbi, 2000; Di
Prospero and f ischbeck, 2005; Evereil and Wood, 2004; Ranum and Day, 2002.
flisease Gene Locus Protein Repeat size
Normal Disease
Non-coding repeats
Friedreich ataxia (FRDA) fXN 9q13-q21.l frataxin 7-34 >100
Fragile X syndrome A fMRI Xq27.3 Fragile X mental 6-53 >230
(FRAXF) retardation 1 protein
Fragile X syndrome E FMR2 Zq28 Fragile X mental 6-35 >200
(FRAXE) retardation 2 protein
Dysftophia myotonica 1 DMPK 19q13 Dystrophia myotomca 5-37 >50
(DM) protein kinase
Spinocerebellar ataxia 8 Antisense to 13q21 Undetennined 15-91 100-155
(SCA8) KLHLJ
Spinocerebellar ataxia 12 F?P2R23 5q3 1q33 Regulatory subunit of 7-28 66-78
(SCA12) the protein phosphatase
PP2A
Huntington disease-like 2 JPH3 1 6q24.3 Junctophilin 3 6-27 51-57
(HDL2)
Potygtutamiue disorders
Spinal and bulbar muscular AR Xql 3q2 1 Androgen receptor 9-36 3 8-62
atrophy (SBMA)
Huntington’s disease (HD) 1T15 4pl6.3 Hunfingtin 6-35 36-121
Dentatombral- DRFLA l2pl3.3l Atrophin 1 6-35 49-88
pallidoluysian atrophy
(DRPLA)
Spinocerebellar ataxia 1 SCA I 6p23 Ataxin 1 6-44 3 9-82
(SCA 1)
Spinocerebellar ataxia 2 SCA2 12q24.1 Ataxin 2 15-31 36-63
(SCA2)
Spinocerebellar ataxia 3 SCA3/MJD 14q32.l Ataxin 3 12-40 55-$4
(Machado-Joseph
disease) (SCA3/MJD)
Spinocerebellar ataxia 6 CA CNA lA l9pl3 ŒIA-voltage-dependent 4-1 $ 21-33
(SCA6) calcium channel subunit
Spinocerebellar ataxia 7 SCA7 3pl2p13 Ataxia 7 4-35 37-306
(SCA7)
Spinocerebellar ataxia 17 TBP 6p27 TATA box binding 25-42 45-63
(SCA17) protein
41.2 Pathogenesis of polyglutamine dïsorders
Nine neurodegenerative disorders (SBMA, HD, DRPLA and SCAs 1, 2, 3, 6, 7, 17), are
caused by CAG repeat expansions within the coding sequence ofthe respective genes.
Aside from their expanded polyglutamine tract, the mutant proteins do flot share any
homology, but the diseases have similar features and probabiy share common
mechanisms ofpathogenesis (Cummings and Zhoghbi, 2000).
The first simiiarity is the mode of inheritance. With the exception of SBMA, which is X
linked, ail ofthese diseases are inherited in an autosomal dominant fashion.
Secondly, the progression and manifestations ofthe diseases are characterized by similar
events. Neurodegeneration develops progressively, appears in midiife, and causes
increasing neuronal dysfunction which eventually leads to neuronal loss 10-20 years
following the onset of symptoms (Zoghbi and Off, 2000). Also, the age of onset is an
exponential function that is inversely dependent on the number of the repeats; that is,
longer expansions lead to an earlier age of onset with more severe manifestations (Zoghbi
and Orr, 2000). Polyglutamine disorders also display one ofthe fundarnental features of
neurodegenerative diseases: neuronal ce!! death is apparent only towards adulthood,
despite expression ofthe mutant protein throughout life. This suggests that accumulation
of the toxic product or cumulative cellular damage reaches a threshold beyond which the
neuron cannot compensate (Paulson, 1999).
5Thirdly, another phenomenon observed in affected families is genetic anticipation: over
successive generations, the diseases present an earlier age of onset and progress more
rapidly due to successive expansions ofthe CAG tract during transmission (Zoghbi and
Off, 2000).
Fourthly, in ail of these diseases, only neuronal celis are specifically targeted by the
mutant proteins. Moreover, only a selected subset ofneurons (specific for each disorder)
is affected by apoptosis, despite widespread expression of mutant protein in the nervous
system and throughout the body (Paulson et al., 1997a; Reddy and Housman, 1997;
Zoghbi and Orr, 2000).
Fifthly, neuronal accumulation of mutant protein in nuclear or cytoplasmic inclusions is a
common feature to ail polyglutamine diseases (Ross and Poirier, 2004; Michalik and van
Broeckhoven, 2003). Mutant polyglutamine-containing proteins aggregate in vulnerable
neurons and these aggregates are also positive for ubiquitin and proteasome components
(Cummings and Zhoghbi, 2000). Though the presence ofthese nuclear inclusions may
appear to be the cause of neuronal dysfunction, this link remains uncertain as several
reports have indicated that they are neither necessary nor sufficient to initiate
polyglutamine-mediated disease (Cummings and Zhoghbi, 2000). Nevertheless, the
commonalities of inclusion formation in many unrelated neurodegenerative diseases
might reflect a shared coping response to diffuse toxic proteins and indicate a common
pathological mechanism (Ross, 1997).
6And finally, transcriptional dysregulation appears to represent a unifying pathogenic
mechanism in polyglutamine disorders, as profound transcriptional changes are oflen
noted in cadi case (Evert et ciL, 2003).
In spite ofthe many similarities among polyglutamine disorders, as reflected by the
abundant publications looking into common mechanisms oftoxicity, it is important to
note that each disease is nonetheless distinct and characterized by unique properties. for
example, each is caused by a different gene, located on different chromosomes.
Furtherrnore, each possesses a characteristic critical threshold for glutamine repeat
number, below which the disease does not occur (Gusella and Macdonald, 2000). Also,
the brain regions affected are flot identical (Margolis, 2003). Therefore, the protein
context and neuronal cell-type affected in the various disorders present differences
unique to each disease and must be investigated individually.
1.3 Characterïstïcs ofspinocerebellar ataxia type-3 (SCA3)
1.3.1 Clinical and pathological features
SCA3 is a neurodegenerative disorder also called Machado-Joseph disease (MJD). The
clinical features of SCA3 patients include cerebellar ataxia, oculomotor abnormalities,
spasticity, peripheral neuropathy, and cognitive disturbances (Dûrr et al., 1996). Core
features include progressive ataxia, dysarthria, postural instability, nystagmus, eyelid
retraction, and facial fasciculations. Dystonia is often prominent in younger patients
(Sudarsky and Coutinho, 1995). five subtypes ofthe disease have been identified; the
7most common, type 2, is associated with early adulthood to middle-age onset (20-45
years) and its clinical manifestations are cerebellar and pyramidal signs (Margolis, 2003).
The pathology of SCA3 is associated with neurodegeneration occurring mainly in the
basal ganglia (substantia nigra), brain stem, spinal cord, pontine nuclei, and cerebellum
with preservation of cerebellar cortex and inferior olive (DUrr et al., 1996; Paulson et al.,
1997a; Sudarsky and Coutinho, 1995). The neuropathy involves both sensory and motor
neurons in myelinated and unmyelinated fibers (Margolis, 2003).
Currently, there is no treatment or cure for SCA3, but identification of the mutant gene
has been useful for diagnosis and genetic counselling (Colomer Gould, 2005).
1.3.2 Molecular genetics of SCA3
This disease is an autosomal dominantly-inherited ataxia originally described in people of
AzoreanlPortuguese descent. The disorder has subsequently been identified in many
other countries including Japan, Brazil, Australia, and China (Sudarsky and Coutinho,
1995).
The cause of SCA3, the most common dominantly inherited ataxia, was identified to be
an unstable expansion of a CAG repeat in the human MJDJ gene (Kawaguchi et al.,
1994), which had been previously mapped to chromosome 14q24.4-q32.1 (Takiyama et
al., 1993). The MJD] gene encodes the cytoplasmic protein ataxin-3 of 42 kDa with
8ubiquitous expression throughout the body. Despite this widespread expression,
pathological sites are selective to certain brain regions only (Paulson et al., 1997a).
The number of normal CAG repeats ranges from 10-5 1, whereas the expanded CAG
length is from 55-86; however, intermediate repeat lengths of 53 and 54 have been
observed in SCA3 patients who display an abnormal phenotype (van Alfen et al., 2001;
Zhou et aÏ., 1997). These expanded repeats are highly unstable and may expand from
one generation to the next, which explains the anticipation observed in patients (Galvao
et al., 2004). Large changes in CAG repeat number are also more frequently associated
with paternal transmissions, suggesting the expansion occurs during the pre-meiotic
proliferative stages of spermatogonial divisions (Galvao et al., 2004; Pearson et al.,
2005).
An interesting observation is that despite being an autosomal dominant disorder, clinical
studies have shown that SCA3 patients homozygous for the mutation display more severe
symptoms at an earlier age than heterozygotes (Lerer et al., 1996; Sobue et al., 1996;
Zlotogora, 1997). This suggests that in heterozygotes, the second non-mutant allele may
act protectively to reduce the age at onset or that dosage ofrepeat-bearing proteins may
be important for pathogenesis.
91.3.3 CeIlular features of the disease
1.3.3.1 Misfolded polyglutamine proteins
The polyglutamine proteins produced by the MJDJ gene with expanded-CAG repeats are
prone to misfolding (Jana and Nukina, 2004). The first une ofcellular defence against
these proteins involves molecular chaperones, which participate in refolding abnormal
peptide conformations (McClellan and Frydman, 2001). Secondly, if this system fails,
the defective proteins are tagged with ubiquitin and targeted for degradation by the
proteasorne complex (Goldberg, 2003; Ciechanover and Brundin, 2003). Thirdly, if the
misfolded proteins cannot be removed, they form aggregates which the ceil attempts to
remove by autophagy (Ravikumar et al., 2004).
Lastïy, it was observed that when mutant ataxin-3 binds to the nuclear matrix, this causes
a conformational change which exposes the polyglutamine tract (Perez et al., 1999).
Upon exposure of the expanded tract, more aggregation and binding of other
polyglutamine-containing proteins occur. If removal of these aggregates is unsuccessful,
they ultimately grow in size and form into larger nuclear inclusions (NIs), a hallmark of
polyglutamine diseases (Jana and Nukina, 2004).
1.3.3.2 Inclusions in SCA3 affected brain regions
In SCA3 patients, the presence of visible nuclear inclusions (NIs) ofvarious sizes was
detected in brain tissue (Paulson et al., 1 997a). Inclusions containing mutant ataxin-3
protein were observed in regions such as the cerebral cortex, striatum, thalamus, and
10
lateral geniculate body (Yamada et al., 2004). Interestingly, NIs were even detected in
regions ofthe nervous system that showed no obvious neuronal loss (Yamada et al.,
2001 a).
1.3.3.3 Formation of inclusions
Nuclear inclusions are most likely a manifestation ofmisfolding and aggregation ofthe
mutant protein, and as a consequence, lead to aberrant protein-protein interactions within
affected ceils (Chai et al., 2001). Studies suggest that NIs in polyglutamine diseases arise
from nuclear bodies (NBs), which are intranuclear structures that function in
transcriptional regulation, growth suppression and apoptotic ccli death, and are fourni
distributed throughout the nucieus in a speckled pattern (Seeier and Dejean, 1999; Zhong
et al., 2000). The appearance of large macroscopic inclusions characteristic of SCA3 is
preceded by the presence of insoluble, micro-aggregates of mutant ataxin-3 (Chai et al.,
2001). These authors found that in SCA3, expanded polyglutamine co-iocalized with
promyelocytic leukemia protein (PML), an essential component ofNBs (Takahashi et al.,
2003). This suggests that NBs are gradually enriched in misfolded mutant proteins and
eventuaily iose their characteristic structure due to the excessive accumulation of mutant
proteins.
1.3.3.4 Mechanism of aggregation
Pemtz et al. (1994) proposed that the glutamine repeats act as polar zippers: they are
capable of linking 3-strands together into sheets by networks of hydrogen bonds between
11
their main-chain amides and polar side chains; this cross-Ïinking would allow for the
joining of complementary proteins, resulting in the formation of insoluble aggregates.
The expansion of glutamines might cause the mutated protein to acquire non-specffic or
increased affinity for each other or for other glutamine-containing proteins, thereby
causing pathological defects (Perutz et al., 1994; Stott et al., 1995). However, this cross
linking in the presence ofthe mutant protein context was not as apparent (Perutz et al.,
1994).
Altematively, Green H. (1993) proposed that aggregation was based on the activity ofa
transglutaminase enzyme which links the amino groups of lysine residues in other
proteins through isopeptide bonds to form covalently bonded aggregates. In fact,
huntingtin, a polyglutamine disease protein, was shown to be a substrate for brain
transglutaminase and its aggregation was dependent on Ca2 levels, which are linked to
impulse-conduction in neurons (Kahiem et al., 1996; Kahlem et al., 1998).
Neither of these processes has been demonstrated in vivo. Whichever the mechanism
may be, it appears that the proteins are destabilized and drawn into the nucleus, where
ubiquitination and aggregation occur.
1.3.3.5 Components of inclusions
Inclusions are composed ofnot only the mutant protein, but also other cellular factors
which might provide insights into the aberrant protein-protein interactions that occur
prior to cell death. 0f interest is the presence of the wild-type ataxin-3 protein (with a
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non-pathogenic polyglutamine length) within inclusions. Studies have found that wild
type ataxin-3 can accumulate in eosinophilic nuclear inclusions, or Marinesco bodies, in
the absence of expanded polyglutamines under stress conditions such as aging; in this
case, wild-type ataxin-3 may play a role in the ubiquitination of other proteins
(Fuj igasaka et al., 2000). On the other hand, it can also be recmited to mutant protein
containing inclusions in the presence ofpathologically expanded polyglutamine (Paulson
et aï., 1997b; Uchihara et al., 2001).
As the inclusions contain misfolded proteins, it is common to also detect the presence of
molecular chaperones, ubiquitin (a cellular modification used to tag proteins for
degradation), and proteasomal components, part ofthe cell’s protein degradation
machinery (Paulson et al., 1997b; Chai et al., 1999b).
1.3.3.6 Fate of inclusions
Several reports have shown that inclusions are highly ubiquitylated and that the
proteasome complex redistributes into polyglutamine aggregates formed by the disease
protein ataxin-3; this suggests proteasome function is closely linked to aggregate
formation (Chai et al., 1999b; Schmidt et al., 2002). In addition, it was also observed
that proteasomal inhibitors promoted aggregation of mutant ataxin-3, suggesting an
involvernent of the protein surveillance machinery in suppression of aggregation (Chai et
al. 1999b).
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Evidence from SCA3 patient brains, obtained by immunohistochemical analysis of
neuronal NIs in pontine neurons, revealed the presence of chaperones in the Hsp4O
family along with subunits of the proteasomal proteolytic machinery. As this rnachinery
was detected in only a fraction ofthe pontine neurons, this suggests proteasomal
perturbations in specific regions in these brains (Schmidt et al., 2002). Overali, these
resuits suggest that inclusions are ultimateÏy destined to undergo proteasome-mediated
degradation.
Though the ubiquitin-proteasomal pathway is frequently referred to as the only pathway
responsible for the clearance ofprotein aggregates, studies have shown that the
autophagy-lysosomal pathway is also involved in the removal of the aggregate-prone
polyglutamine and polyalanine proteins (Ravikumar et al., 2002).
1.3.3.7 The role of inclusions
The role of inclusions in polyglutamine diseases has been extensively examined in many
cases. Studies have demonstrated that inclusions can be harmful, coincidental, or even
protective (Sisodia, 1998). The formation ofNls may be the underlying cause of neuronal
dysfunction in polyglutamine diseases; however, these disruptions do flot invariably bring
about celi death (Davies et al., 1997). In many of the cases studied, the correlation
between the presence of nuclear inclusions and ceil death was poor, suggesting that
inclusions are not necessarily the primary toxic insuit (Everett and Wood, 2004).
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Moreover, it has been reported that in Huntington’s disease, inclusion formation actually
promotes ccli suwival in neurons (Arrasate et al., 2004). These resuits indicate that
inclusion formation might protect neurons by decreasing the levels oftoxic diffuse and
soluble forms of mutant protein. Evidence in SCA7 demonstrated that extensive
inclusion formation leads to reduced symptoms, but is nonetheless insufficient to hait the
disease, as the system is eventually overwhelmed and results in neuronal dysfunction
(Bowman et al., 2005). When aggregates were present in one brain region (the pons), the
size and shape ofthe neuronal nuclei were more preserved than in neurons without
inclusions. This suggests that inclusions are not necessarily toxic to neurons ofdiseased
brains (Uchihara et al., 2002). There is also a debate over whether large aggregates or
small invisible aggregates directly cause ccli death (Zhoghbi and Orr, 2000).
Notwithstanding, the presence ofNls is critical, as it likely represents a biological marker
for the underlying pathogenic process (Chai et al., 2001). Aggregation could help
explain why polyglutamine toxicity only affects neurons. Since these celis are post
mitotic, the aggregate load is flot reduced when the nuclear membrane disintegrates, as it
happens in dividing cells, where the aggregates are distributed to the cytoplasm of
daughter cells (Michalik and Van Broeckhoven, 2003). It was shown in a SCA3 ccli
culture model that ccli cycle arrest enhances toxicity (Yoshizawa et al., 2000); also, in a
fty SCA3 model, ccli death was observed only in post-mitotic cells ofthe eyes, flot the
diving ceils of imaginai discs (Warrick et al., 1998). As neurons are known to be
arrested in G0 phase, these resuits possibly explain why they are more vulnerable than
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other types of ceils in SCA3. The selective death of specific fleurons, however, remains
unexplained.
1.3.4 Structure of ataxin-3 protein
The ataxin-3 protein, coded by the MJD] gene, is an intracellular protein of 42 kDa with
mostly cytoplasmic expression, but is also found in neuronal nuclei of SCA3 patients
(Paulson et al., 1 997a) and is therefore predicted to contain a nuclear localization signal
(Tait et al., 1998). The protein contains an amino (N)-terminal Josephin domain (JD),
two ubiquitin (Ub)-interacting motifs (UIMs), a polyglutamine stretch and a short
variable C-terminal tau (Goto et al., 1997) (Figure 1.1). A rare spiice variant containing
a third putative UIM in the carboxyl (C)-terminal was also identified by the same group.
The ID appears to contain a catalytic cysteine protease with deubiquitinase activity
(Scheel et al., 2003). The UIM is a conserved 15- amino acid motif for binding
polyubiquitin chains (Chai et al., 2004) and plays an important role in both the catalytic
activity of ataxin-3 and the deubiquitinating reaction as a chain-editing enzyme that
shortens Ub chains (Mao et al., 2005). Therefore, the UIM can bind to ubiquitinated
proteins that accumulate when the proteasorne is inhibited and the ID can function to de
ubiquitinate these proteins or even itseÏf in trans (Berke et al., 2005).
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Figure 1.1 Structure of the ataxin-3 protein containing an N-terminal Josephin domain with a predicted
ubiquitin-specific protease with catalytic triad (Cys’4, Histl9, and Asn’36), a coiled-coil dornain, a C-
terminal ubiquitin-interacting motifs (UIMs), and a polyglutamine tau Q(n). Berke SJS et aÏ., (2005) J.
Biol. Chem. 280:32026-32034.
1.3.5 Functions of ataxin-3 protein
1.3.5.1 Protein maintenance activity
The physiological function of ataxin-3 is stili unknown. There is strong evidence
pointing towards its involvement in the ubiquitin-proteasome system (see figure 1.1).
Ubiquitin-dependent pathways are responsible for degradation ofmost cytosolic proteins,
including misfolded and damaged proteins, and are therefore critical for proper protein
quahty control (Ciechanover, 1994).
Studies demonstrate that the ataxin-3 protein can bind polyubiquitin chains of four or
more ubiquitin tags through its UIM and that binding is equally effective in both wild
type and pathological ataxin-3 (Burnett et al., 2003). Moreover, UIMs are primarily
responsible for inhibiting degradation through binding ofubiquitylated proteins and thus
preventing access to the proteasome (Bumett and Pittman, 2005). The decreased
degradation by the proteasome is, therefore, indirectly mediated by alteration ofthe
substrate via ataxin-3 and flot through a direct effect on the proteasome itself (Bumett and
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Pittman, 2005). The ataxin-3 protein also lias ubiquitin protease activity that removes
polyubiquitin chains, with cysteine-14 being the catalytic site on the protein, and also
binds an active site inhibitor of ubiquitin protease (Bumett et al., 2003).
More recently, Warrick et al., (2005), demonstrated that normal ataxin-3 was recruited to
NIs and helped to reduce accumulation ofpathogenic protein in a Drosophila SCA3
model. Furthermore, this protective activity was mediated by the ubiquitin-proteasomal
pathway. In addition, this intrinsic activity was even able to suppress toxicity of other
polyglutamine disease proteins, such as huntingtin in Huntington’s disease and ataxin-1
in SCA1. These resuits may explain the fact that although SCA3 is an autosomal
dominant disorder, homozygotes display a more severe phenotype due to the cumulative
effects ofthe loss ofthe protective function ofthe wild-type protein in conjunction with
the gain of a novel function of the mutant protein when both alleles are mutated.
As for the role of mutant ataxin-3 in SCA3 pathology, evidence by Berke et al. (2005)
shows that the proteasome efficiently degrades both normal and expanded ataxin-3
proteins and that proteasome inhibition by soluble expanded ataxin-3 does not appear to
play a major role in SCA3 pathogenesis. In general, the presence of a polyglutamine
expansion does flot dramatically impair proteasome activity under basal conditions, but
does significantly impair its ability to respond to stress and increases stress-induced
protein aggregation following stress (Ding et al., 2002), suggesting the pathology is
complex and involves other cellular disruptions.
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Although more dues are being revealed about the proteasomal inhibitory functions of this
protein, it is flot yet clear how essential wild-type ataxin-3 function is to the pathway, and
whether mutant ataxin-3 directly or indirectly alters its function, if at ail. Initial reports
suggest that the expansion modulates wild-type ataxin-3 protease activity andlor the
range of its substrates, but whether or not this function is linked to the disease pathology
has yet to be determined (Bumett et al., 2003). It is further hypothesized that
pathological ataxin-3 and misfolded denatured proteins, coupled with decreased
proteasome activity due to aggregation, would increase the likelihood ofthis continued
process and, over time, would resuit in inadequate degradation ofmany cellular
regulators resulting in cellular dysfunction (Bumett et al., 2003).
Another protein maintenance function of the endogenous ataxin-3 has to do with its
association with histone deacetylase 6 (HDAC6), a protein that binds to polyubiquitinated
substrates (Kawaguchi et al., 2003), and the ATPase motor protein dynein that transports
various cellular cargos along cytoskeletal microtobules towards the center ofthe ce!!
(Va!lee et al., 2004). The association ofthese three proteins - ataxin-3, HDAC6, and
dynein - is responsible for trafficking aggregated proteins within the ce!! to form
aggresomes (Bumett and Pittman, 2005).
Therefore, it appears that wild-type ataxin-3 is first recruited to bind and trim ubiquiting
chains on misfo!ded ubiquitylated proteins, shie!ding them from the proteasome; then its
deubiquitin activity and UIMs are required for aggresome formation and for ataxin-3 to
associate with dynein and HDAC6 to facilitate transport of the misfolded protein to the
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microtubule organizing center (MTOC) for formation of aggresomes (Burnett and
Pittman, 2005).
1.3.5.1 Transcriptional regulator activity
The second proposed function of ataxin-3 is its involvement in transcriptional regulation.
Research by Li et al., (2002) has shown that endogenous ataxin-3 interacts with key
regulators of transcription and acts to repress transcription via multiple mechanisms. The
polyglutamine-containing C-terminus ofthe protein is able to repress transcription when
targeted to chrornatin. Furthermore, the glutamine rich C-terminus binds to the
transcriptionai coactivators CREB-binding protein (CBP), p300, and PCAF, ail ofwhich
have intrinsic histone acetyltransferase activity (Cho et al., 199$); ataxin-3 was shown to
inhibit their abiiity to activate transcription. As an indication towards a pathological
effect, the expanded polygiutamine repeats of ataxin-3 bind to transcription coactivators
with a higher affinity than the normal iength polyglutamine repeats protein.
This group also identified a second mechanism of transcriptional repression by full
length ataxin-3: the N-terminus of the protein was shown to bind and mask H3 and H4
histones and prevent acetylation by p300, thereby decreasing transcriptional accessibility.
Despite what is known about its function, the specific targets of ataxin-3 in pathogenesis
of SCA3 have yet to be determined. It is believed, however, that transcriptional
dysregulation is irnplicated in the disease process.
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1.4 Objectives and thesis outiine
The purpose ofthis study is to gain further insight into specific aspects ofthe pathology
ofSCA3 at the cellular level. Following this introductory chapter (Chapter 1), this
rnanuscript is composed ofthree experirnental chapters, each with specific objectives
designed to focus on one aspect ofthe disease. The first objective is to develop and
characterize SCA3 model systems to be used in the following chapters (Chapter 2). The
second objective is to build on the theory ofribosomal frameshifiing in SCA3
pathogenesis, an aspect that has been previously reported by our lab (Chapter 3). The
third objective is to investigate one mechanism of transcriptional dysregulation in the
disease progression (Chapter 4). The last chapter is a general conclusion which
summarizes this study and discusses possible therapeutic applications (Chapter 5).
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Chapter 2: Model systems of SCA3
2.1 Introduction: established models of SCA3
2.1.1 Mouse models
Mouse models are the preferred choice for the study ofhuman diseases because they are
a good represention ofthe mammalian systems; in addition, they are small and short
lived, breed quickly to generate relatively large numbers, and can be used for invasive
procedures (Colomer Gould, 2005). Transgenic mice expressing mutant full-length and
truncated (C-terminal fragments containing the glutamine tract) versions ofthe ataxin-3
protein have been generated for research purposes (flceda et al., 1996; CernaI et al., 2002;
Goti et al., 2004). Particularly, the mice expressing the truncated version displayed
massive degeneration of the cerebellum and developed ataxia by four weeks of age. In
contrast, expression of fuil-length mutant ataxin-3 in mice failed to show any pathology
(Ikeda et aÏ., 1996). From this mode!, researchers proposed that, since the truncated
version was toxic, proteolytic cleavage of the mutant protein might occur to liberate the
polyglutamine tract, which leads to death ofneurons. further evidence by Wellington et
al. (1998) demonstrated that ataxin-3 can be cleaved by a caspase. The generation ofa
third mouse model led to different resuits through widespread expression ofhuman yeast
artificial chromosome (YAC) constructs encompassing the MJDJ locus; cerebellar ataxia
and neurodegeneration were observed in the absence of a cleaved ataxin-3 fragment
(Cernai et al., 2002). A fourth mouse mode! developed by Goti et al. (2004) was
established via the expression of full-iength hurnan mutant MJD]a cDNAs. These
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animais displayed abnormai behaviour with prominent neuronal nuclear inclusions in
selective brain regions and in the spinal cord. Unique to this iast model, however, was
the finding that flot only the mutant ataxin-3, but aiso its putative-cleavage fragment,
were enriched in nuclear fractions ofbrain homogenates. Aitogether, these mouse
models have been important for the eiucidation ofthe mechanisms ofdisease
pathogenesis and progression in human.
2.1.2 Invertebrate models: Drosophila
The fruit fly, Drosophila ,netanogaster, has been used as an experimentai organism for
many human neurodegenerative diseases. The first polyglutamine disease modeled in
Drosophila was SCA3. Warrick et al. (1998) expressed a truncated ataxin-3 protein
(containing 12 amino acids ofataxin-3 upstream ofthe giutamine repeat, the expanded
glutamine repeat, and the 43 amino acids comprising the carboxy-terminus of the protein)
in fly eyes and observed both retinal degeneration and nuciear inclusions in the
photoreceptor cells of developing eye discs. Furthermore, they showed that the
deieterious effect ofthe expanded mutant protein could be prevented by co-expression of
P35, an antiapoptotic agent, which partiaiiy restored pigmentation ofthe eye. Another
group, Ghosh and Feany (2004), also modeled SCA3 in flics, but examined neurotoxicity
in brain regions in an attempt to determine whether common pathways of toxicity govem
neurodegeneration in the eye and brain. Using the same truncated ataxin-3 protein as the
previous group, expression in this case showed ceii-type vuinerability and demonstrated
retina-specific effects. Expression of expanded ataxin-3 in the brain caused toxicity to
Kenyon ceils, the projection neurons ofthe mushroom bodies, structures impiicated in
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leaming and memory. Using this model, the authors were able to show that
overexpression of the molecular chaperone Hsp7O can suppress polyglutamine-induced
neurodegeneration. In addition, antiapoptotic therapies were shown to be beneficial to
the toxicity associated with SCA3 and possibly other neurodegenerative disorders. More
recently, Warrick et al., (2005) expressed a full-length ataxin-3 constnict in flues and
found that ataxin-3 accumulated in ubiquitinated inclusions and that the full-length
protein is more selectively toxic to the nervous system. Each ofthese Drosophila models
lias provided unique insights to various aspects of the human disease.
2.1.3 In vitro or cellular models
Ceil models are often used to study specific aspects ofneurodegenerative diseases
because they are versatile and easy to manipulate; however, these models are unable to
reproduce the breadth of pathological events that happen in the human brain and thus
remain of limited interest. Several groups were able to model SCA3 in ceil culture to
illustrate the cellular expression and interactions of the mutant protein. Full-length
ataxin-3 expression appears in the cytoplasm and nucleus, where the protein is associated
with the nuclear matrix (ilceda et al., 1996; Paulson et al., 1997b; Tait et al., 199$). The
mutant full-length ataxin-3 also forms aggregates in these ceil models, but with less
efficiency and less toxicity than the truncated version. Also, transfected celis show
indentations ofthe nuclear envelope and undergo spontaneous non-apoptotic ceil death
(Ikeda et al., 1996; Paulson et al., 19975; Evert et al., 1999). The importance ofnuclear
localization of the protein for aggregate formation was shown using fulI-length ataxin-3
which was recruited from the cytoplasm into nuclear inclusions by a non-reÏated
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glutamine-rich repeat (Perez et al., 1998). Furthermore, the involvement ofthe
proteasomal degradation system was also identified in ce!! models and its co-localization
to inclusions was demonstrated by others (Chai et al., 1999b). It was further shown that
Hsp4O chaperones suppress ataxin-3 aggregation in neural and non-neural cells and that
this reduction in aggregation was associated with a decrease in neurotoxicity (Chai et al.,
1999a). This evidence suggests a toxic role for aggregates in this cellu!ar model. And
finally, a novel aspect of SCA3 was revea!ed in a Cos-1 ce!! culture model by Gaspar et
al. (2000) and Toulouse et al. (2005) in our lab; it was demonstrated that ribosomal
frameshifiing occurs in the long CAG repeats ofthe truncated MJDJ constructs which
leads to the production ofpolyalanine-containing proteins. It is believed that these
proteins, which were shown to be more toxic, play a role in pathogenesis ofthe disease.
Toulouse et aï. demonstrated this toxicity by using two constructs with different repeats,
CAG and CAA, both ofwhich code for polyglutamine; however, only the CAG construct
can frameshift into the -1 frame to produce a polyalanine-encoding protein. Therefore,
the practicality and simplicity ofthese cellular models are essential as a first step for
studying disease processes in a control!ed and reproducible environment.
2.2 Objectives
The objective ofthis chapter is to establish a fuIl-length cellular SCA3 mode! by
generating three full-length MJD 1 constructs of different repeat lengths and types, tagged
in the three reading frames, and to characterize their expression in Cos-1 cells. Aside
from using the full-length of the gene, the tags used in this model will be more easily
detectable than the ones used in our previous model established by Toulouse et al.,
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(2005). Secondly, using a Drosophila model also expressing full-Ïength ataxin-3
previously established in our laboratory, we aim to characterize the phenotype ofthese
flues so they can be used for further experiments and to test potential treatments.
2.3 Materïals and Methods
2.2.1 CeIlular model: generation of plasmid constructs
The original full-length MJDJ cDNA was obtained from a previous construct (Ichikawa
et al., 2001). Modifications were made to generate the constructs used by Toulouse et
al., (2005). Subsequent alterations were made by others in our lab. Here, we will only
describe the modifications made to generate the constmcts used in this study.
The CAG9 expression construct was generated from a previously made construct in
pEGFP vector. The sequence was amplified by PCR using primers 2491
pMJD 16(5_HindIll_1)F (5 ‘-AGAGACGAGAAGCCTACTTTAAGCTTCAGCA
GCAACAGCAGCAGCAACAGCA-3’) and 2492 pMJD16(3_EcoRl_v3)R (5’-
GGATGTGAATTCCTGTCCTGATAGGTCCCGCTGCTGCT-3’).
Full-length human MJD-] cDNAs with either 98 CAG or 94 CAA repeats from a
previously generated construct in pBSII (Bluescript vector) were amplified by PCR using
primers 2637 MJD(BZO7BamHI)F (5 ‘-CGGTACCCGGGATCC-AGACAAATAA-3’)
and 2638 MJD(BZO7 TAG-TAC)R (5 ‘-CGCGTCGACTCAGTGATGATGGTGGTG
ATGATGATCCATTGAGGT-3’).
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The PCR reaction conditions were the following: 1 Ong DNA template, 5 jtL 1 OX PCR
buffer, dNTPs (25 mM each), Primers (100 ng!iL each), 0.5 L Native Ffu (Pyrococcus
furiosus) DNA polymerase enzyme (Stratagene), and sterile water to a final volume of 50
tL. The touchdown PCR settings were 94°C for 45 sec, followed by 25 cycles of 94°C
for 45 sec, 63°C (decreasing at 0.5°C per cycle) for 45 sec, 72°C for 90 mm, followed by
10 cycles of 94°C for 45 sec, 58°C for 45 sec, 72°C for 90 mm, and finished with 72°C
for 5 min. Products were visualized on 1% agarose gel. Bands were excised and purified
using QIAEX II Gel Extraction Kit (Qiagen). Purified band products were resuspended
in 20 jiL ofH2O and 2 L ofthis product was mn on a 1% agarose gel to confirm desired
products were obtained.
Addition of 3’ A-overhangs post-amplification for subcIoning was carried out by mixing
the remaining 1$ jiL with 3 tL of 1OXPCR buffer, 3.5 .tL dNTP, and Taq (Thermus
aquaticus) poiymerase (Stratagene) and incubating at 72°C for 15 min. The TOPO TA
Cloning Kit (Invitrogen) was used for the rest ofthe steps. The TOPO Cloning Reaction
was done using 4 .tL ofthe DNA with 3’ A-overhangs, 1 tL of sait solution, and 1 tL of
the pCR2. 1-TOPO vector. Reactants were mixed gently and incubated at room
temperature for 30 min. Transformation using the One Shot DH5a-T1 Competent Ceils
was done by adding 2 jiL ofthe TOPO Cloning reaction to 50 !IL ofthe competent cells
and mixed gently. Cells were then placed on ice for 30 mm, heat-shocked at 42°C for 30
sec, placed on ice for 5 mm, and 300 iiL ofS.O.C. medium was added. Ceils were plated
at 2 volumes (50 p.L and 350 tL) onto Luria-Bertani (LB) Medium plates (with 50
.tg/mL ampicillin, 40 iiL WTG, and 40 jiL X-Gal) and incubated ovemight at 37°C.
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Analysis of positive clones was performed by selecting white colonies and culturing them
in 3 mL of LB (with 50.tg/mL ampicillin) ovemight at 37°C. Isolation of plasmid DNA
was done using the Qiafilter Plasmid Mini Kit (Qiagen). Transformants were analysed
by restriction enzyme digestion with enzymes XhoI (Invitrogen) and SacI (New England
BioLabs) for construct CAG9 (reaction conditions: 14 iL FI2O, 2 iL Buffer NEB2 (New
England BioLabs), 0.5 rL XhoI, 0.5 tL ScaI, and 3 tL DNA), and BamHI (Invitrogen)
and SalI (New England BioLabs) for constructs CAG100 and CAA96 (reaction
conditions: 13.8 1iL E120, 2 1iL Buffer NEB3 (New England BioLabs), 10 mg!mL bovine
serum albumin (BSA), 0.5 tL BamHI, 0.5 iL SalI, and 3 tL DNA). Reagents were
incubated for 3 hrs at 37°C and analyzed on 1% agarose gel. Positive transformants were
also analyzed by sequencing (2 j.tg ofplasmid DNA in 50 jiL H20 with M13f and M13R
primers).
Positively selected DNA plasmids in TOPO vector (for CAG1 00 and CAA96 constructs)
were then subj ected to restriction enzyme digestion to cut out the insert of interest (using
2 ig ofDNA with enzymes BamHI (Invitrogen) and Sal I (New England BioLabs)), and
so was the final pEGFP-Nlvector (Clontech Laboratories) (using 200 ng/iL ofvector
with enzymes BglII (New England BioLabs) and SalI (New England BioLabs)).
Confirmation of digestion was visualized on 1% agarose gel. Ligation was carried out by
combining the 3 iL digested vector, 6 tL insert, 4 tL 5X buffer, 6 jiL H20, and 1 jiL T4
Ligase enzyme (New England BioLabs), and incubating the reaction at room temperature
for 4 hrs. Transformation was done by adding 3 iL of ligation product to 50 jiL of
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competent E. cou celis, placed on ice for 30 mm, heat-shocked for 30 sec at 42°C, placed
on ice for 2 mm, followed by addition of 450 tL of LB and incubation at 37°C for 1 hr.
Ceils were then plated at 2 volumes (50 jiL and 450 tL) onto kanamycin plates (0.025
mg/mI) and grown ovemight at 37°C. Positive colonies were selected as previously
described above and grown in 3 mL LB with kanamycin. DNA plasmids were extracted
same as previously, and confirmation of insert incorporation was done by restriction
enzyme digestion with NheI (New England BioLabs) and ApaI (New England BioLabs)
enzymes. Positive colonies were then grown in 400 j.tL LB with kanamycin overnight
and isolation ofplasmid DNA was done using Qiafilter Plasmid Maxi Kit (Qiagen). All
plasmids were confirmed by sequencing.
Additional steps were required to generate the CAG9 construct. The pÏasmid DNA from
the CAG9 construct in TOPO vector was subjected to DNA precipitation and PCR with
Pfii polymerase with primers 2491 and 2492 to arnplify the insert (same conditions as
previously described). This PCR product and the CAG100 construct in pEGfP vector
were subj ected to restriction enzyme digestion with EcoRT (Invitrogen) and Hindiil (New
England BioLabs) to generate the insert (with sticky ends) and vector, respectively. The
insert and vectors were ligated, transformed, selected, and confirmed (same as
previously).
Upon sequence verification ofthe three constructs (CAG9, CAG100, and CAA96), it was
noticed that the EGFP tag was in the -1 frame and not in the main reading frame.
Corrections were made by digesting the constructs with BamHI (Invitrogen) (2 pi DNA,
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0.5 jiL BamHI 2 jiL Buffer React 3 (Invitrogen)), and 15.5 iL H20), and incubating at
37°C ovemight. Blunt ends were fihled in to add 4 nucleotides (to place the tag in the
main frarne) using 3 tL DNA, 3 jiL 1OX Buffer React 3 (Invitrogen), 0.5 jiL Klenow
(Invitrogen), 5 jiL dNTP (1.25mM), and H20 to a final reaction volume of 30 jiL. The
reaction was incubated at 25°C for 30min, stopped by adding 5 tL EDTA (0.5M) and
incubated at 75°C for 20min. Constructs were then subject to ligation, transformation,
selection, and sequence confirmation (same as previously).
Ail final constructs generated contained appropriate repeat lengths, EGFP and Myc
epitope in the mainframe, hemaggiutinin (HA) tag in the -1 frame and His epitope in the
+1 frame (figure 2.1A).
2.2.2 CeIl culture and transient transfections
Ail ceil unes were cultured at 37°C in a humid atmosphere enriched with 5% C02.
Cos-1 and HeLa cells were grown on tissue culture dishes and maintained in Dulbecco’s
modified Eagle’s medium (Gibco-BRL) suppiemented with 10% fetal bovine semm
(Gibco-BRL) and 1% PenicillinlStreptomycin (Gibco-BRL).
for transient transfections, Cos-1 ceils were plated at a density of 150,000 cells per well
on coverslips in six-well plates 24 h before transfection. for protein extraction, celis
were plated directly in six-well plates. Subsequentiy, the medium was removed and $00
iL of Opti-MEM was added to each well and retumed to the 37°C incubator. In parallel,
for each transfection lug ofDNA was diluted in 100 jiL of Opti-MEM and 6 pL of
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PLUS Reagent from the Lipofectamine PLUS Reagent kit (Invitrogen Life
Technologies). The mixture was allowed to stand for 15 min at room temperature. In a
second tube, 5 tL of Lipofectamine Reagent was diluted into 100 iL of Opti-MEM. The
two solutions were combined, mixed gently and incubated at room temperature for 15
min. For each transfection, the Lipofectamine PLUS Reagent - DNA complex mix
solution was overlayed onto the celis and incubated for 3 hrs at 37C. Afler this period, 2
mL of DMEM supplemented with 10% fetal bovine serum and 1%
PeniciÏlinlStreptomycin was added. Celis were retumed to the 3TC incubator for an
additional 4$ hrs.
2.2.3 Fluorescent visualization
Forty-eight hours after transfection, Cos-1 celis were washed in phosphate-buffered
saline (P3 S), fixed for 15 min in 4% paraformaldehyde and washed three times in PBS
and coverslips were mounted on siides using DAPI (4’,6 diamidino-2-phenylindole)
Mounting Medium for Fluorescence (Vector Laboratories), and the localization of full
Iength ataxin-3-EGFP fusion proteins was observed directly with a fluorescence
microscope (Leica DM6000).
2.2.4 Quantification of inclusions
To quantitate the presence of inclusions, we counted ail cells that contained inclusions in
random microscope fields at 200x magnification. Data are expressed as the percentage of
transfected celis containing inclusions.
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2.2.5 Statîstical analysîs
Analysis ofthe statistical significance ofthe frequency of inclusions in celis transfected
with the different constructs was performed using the One-way Anova of variance test.
2.2.6 CeIlular protein extraction and Western blot analysis
Forty-eight hours after transfection, Cos-1 celis were washed in ice-cold PBS and
solubilized for 20 min on ice in non-denaturing RIPA (radioimmunoprecipitation) buffer
(50 mM Tris-HC1 pH 8, 150 mM NaC1, 1% NP-40 (20 mM Tris-HC1 pH 8, 137mM
NaCY, 10% glycerol, 1% nonidet P-40, 2 mM EDTA)), 0.5% sodium deoxycholate, 0.1%
SDS (sodium dodecyl suiphate) supplemented with protease inhibitors (Roche) and
phosphatase inhibitors (10 mM sodium fluoride and 1 mM sodium orthovanadate), and
passed through a 23 gauge needle. Samples were centrifuged at 10 000g for 5 min at
4°C, the supematant was recuperated and protein concentration measured as follows:
Protein concentrations were determined by the Bradford method using Bio-Rad Protein
Assay Dye Reagent Concentrate (Bio-Rad), O.D. values were plotted against a BSA
(New England BioLabs) standard curve and protein concentrations were calculated.
Thirty micrograms ofeach protein extract were aliquoted, boiled for 10 min in 1XSDS
sample buffer (2.4 mL of 1M Tris-Cl pH 6.8, 3 mL of 20% SDS, 3 ml of 100% Glycerol,
1.6 mL ofi3-mercaptoethanol, 0.0006g Bromophenol blue), electrophoresed on an 8%
polyacrylamide gel (SDS-PAGE), and transblotted to a nitrocellulose membrane (Bio-
Rad). Membranes were blocked for 2 hrs at 4°C in 5% milk (instant skim milk powder)
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in PBS-T (0.1% Tween-20 in PBS), incubated ovemight at 4°C with primary antibodies
(Mouse monoclonal anti-ataxin-3 antibody (1:500) (Chemicon International), and Mouse
anti-actin monoclonal antibody (1:10 000) (Chemicon International)) in 5% milk, washed
three times for 10 min in PBS-T, and incubated for 1 h at 4°C with secondary antibody
(Anti-mouse IgG HRP-conjugated antibody (1:10 000)(Cell Signaling Technology)),
followed by three 10 min washes in PBS-T. Immunodetection was performed using the
enhanced chemiluminescence (ECL) system (Perkin Elmer Precisely). Membranes were
exposed to Kodak BioMax MR Films (GE Healthcare).
2.2.7 Drosophila stocks and transgenes
These transgenic flues have been previously characterized within the context of a parallel
ataxin-3 study in our lab (Gaspar et al., manuscript in preparation). Here, were will only
describe the procedures used to obtain and characterize the Drosophila lines necessary
for the present study. Flies bearing CAG92 ami CAA96 transgenic constructs in a
homozygous state were grown at 25°C (or 29°C as stated in the results section) on normal
fly food. Aduit male flues ofthese backgrounds were crossed to virgin gmr-GAL4 flues to
obtain unes driving the expression of the transgenic protein in the developing eye. For a
control cross, male flues of a w1118 background (the original fly stock used for
microinjection of the MJDJ constructs) were crossed with virgin grnr-GAL4 flues to yield
a cross of+/gmr-GAL4 genotype. Full-length MIDi constructs used to make transgenic
flues are shown in figure 2.1B.
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2.2.8 Protein extraction from fly heads
For each fly une (control, CAG92, and CAA96), 30 heads were collected per sample,
added to RIPA lysis buffer supplemented with protease and phosphatase inhibitors (same
as in celis), homogenized, sonicated twice for 10 sec each, and spun at 10 000g for 5 min
at 4°C. The supematant was transferred to a new tube and protein concentration
rneasured as before. Western blot analysis was performed similarly as in celis.
2.2.9 Drosophila model: phenotype characterization
For phenotypic characterization, aduit transgenic flues were observed upon eclosion
(ernergence ofthe aduit insect from the pupal case) and compared to control genotype fly
unes. Aduit flues at day 10 from each constrnct and control were mounted onto a siide
with nail polish, observed on a Leica MZ 12 dissecting microscope and photos were
taken on a Leica DFC 320 camera and digital images assembled using Adobe Photoshop
8.0.
2.4 Results
2.4.1 Distribution and subcellular Iocalization of ataxin-3 in Cos-J
cells
Using the constructs generated, we were able to obtain expression ofthe ataxin-3 protein
in Cos-1 celis. The subcellular localization ofthe enhanced green fluorescent protein
(EGFP)-tagged, full-length ataxin-3 was analyzed by fluorescence microscopy. The
wild-type form of ataxin-3 (CAG9) showed expression in both the cytoplasm and the
34
nucleus (figure 2.2). Similarly, both expanded polyglutamine ataxin-3 constructs
(CAG100 and CAA96) showed diffuse nuclear and cytoplasmic expression. In addition,
celis expressing these two expanded constructs also contained inclusions ofvarious sizes
both in the nucleus and perinuclear region, a cellular feature common to other
polyglutamine diseases. Furthermore, some nuclei ofthe expanded ataxin-3 (CAG100)
expressing celis were ofirregular form, most likely representing dying cells. In other
cellular models, expression of full-length ataxin-3 with normal and expanded repeats
remained diffusely distributed in transfected cells, with most expression found in the
cytoplasm and only a small amount in the nucleus (Paulson et al., 1997b; Perez et al.,
1998; Paulson et al., 1997a). These differences in subcellular localization probably
illustrate that the process is complex and varies depending upon the ceil type and other
cell type-specific factors (Perez et al., 1998). This being said, our full-length cellular
model system, which shows aggregate formation, is in keeping with the mouse and
Drosophila models expressing the full-length ataxin-3 protein; and it also reproduces the
observations made in patients.
2.4.2 Characterization of nuclear inclusions
Inclusion formation in this model was limited to the expanded MIDi constructs only, and
was not detected with the construct of normal repeat length (Figure 2.2). Among cells
expressing the expanded form, flot ail contained inclusions. Inclusions were observed in
24.0% and 14.6% oftransfected cells for the CAG100 and CAA96 constructs,
respectiveiy. The CAG100 expressing cells are thus significantly more prone to form
large visible aggregates than their CAA96 expressing counterpart f(1,20) = 4.43 (P<
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0.05). Both these frequencies are considerably higher than those from other studies,
where full-Ïength expanded ataxin-3 was expressed in different celi types and obtained
either no aggregate formation in 2931 ceils (Perez et al., 1998) or aggregates in less than
1% oftransfected HeLa ceils (Chai et al., 1999b). Furthermore, Toulouse et al., (2005)
also experimented with several ccli types in their cellular model; both aggregation and
frameshifling varied according to celi type. These discrepancies most likeiy reflect celi
type specific differences, since it is known that aggregate formation and subsequent
recruitment ofnuclear proteins to form inclusions can vary widely and thus may
contribute to selective toxicity in neurons observed in polyglutamine diseases (Chai et al.,
2001). These observations underscore the importance ofmodeling the disease in diverse
cdl types and mode! systems, in order to obtain maximum information on the
pathological processes involved.
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Figure 2.1 Schematic representation of fufl-length MJDI constructs. (A) ful]-iength ataxin-3 protein with
various polyglutamine repeat lengths in an EGfP-vector and tagged with three epitopes (HA, Myc, and
His), one in each ofthe reading frames used in the cellular model. (B) FulI-length MJDI constructs used to
generate transgenic flues.
Figure 2.2 Diffuse nuclear and cytoplasmic expression offull-length MiDI constructs. In Cos-l celis
expressing the normal ataxin-3 protein, CAG9, no aggregates are formed. Incelis expressing the mutant
ataxin-3 protein, CAG 100 and CAA96, polyglutamine inclusions form within the nucleus and in the
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2.4.3 Phenotypic characterization of transgenic flies
Expression ofthe polyglutamine expanded transgene CAG92 in flues disrupted eye
morphology (rough eye phenotype) and pigmentation when directed to the developing
eye by using a specific promoter (Figure 2.3). We obsewed moderately abnormal eyes
with the CAG92 fly at 25°C, while at 29°C (a temperature which leads to higher
expression of the transgene) we observed severe discoloration of eye pigmentation and
rough eye phenotype in flics expressing CAG92. It is important to emphasize that this
phenotypic presentation is progressive and ultimately resuits in almost complete ablation
of the eye. Epon embedded sections prepared from the heads of these flues show severe
degeneration and Ïoss ofommatidium cells ofthe eye (Gaspar et al., manuscript in
preparation). The CAA96 transgenic fly did flot show any phenotypic abnormality in
either the eye morphology or pigmentation and was indistinguishable from the non
transgenic, control fly. The reason for this difference may be due to the inabiÏity ofthe
CAA96 constnict to -1 frameshifi during translation ofthe protein and generate a more
toxic polyalanine species, as it happens with the CAG92 construct. This mechanism has
been previously explored by our group and will be further discussed in Chapter 3 of this
manuscript (Gaspar et al., 2000; Toulouse et aÏ., 2005; Gaspar et al., manuscript in
preparation). Altemately, an mRNA toxicity mechanism exclusive to CAG and not to
CAA may partly explain these observations, and is currently under investigation in our
Iab.
.5
Figure 2.3 Expanded-CAG polyglutamine protein causes aduit eye degeneration. Dissecting microscope
pictures ofthe external eyes ofaduit flues expressing CAG92 or CAA96 in the eye at day W, compared to
control flues. The eyes ofCAG92 expressing flues show moderate pigment degeneration compared to
control and CAA96 expressing flues cultured at 25°C, while at 29°C (leading to higher expression ofthe
transgene), they show severe discoloration ofeye pigmentation and rough eye morphology. The eyes of
CAA96 expressing flues displayed no degeneration and appear normal, as in control flues.
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2.4.4 Protein expression of ataxin-3 in celis and flies
Western blot analysis was used to confirm expression ofthe various constructs in
transfected ceil and fly head protein extracts (figure 2.4). Using an anti-ataxin-3
antibody, proteins ofthe expected molecular weights were detected. The endogenous
ataxin-3 protein migrated at ---42 kDa in the Cos-1 ce!! extracts, but is absent in the fly as
invertebrates lack the functional homologue ofthe ataxin-3 protein. In Cos-l celis,
proteins from the wild-type CAG9 construct were detected at -—70 kDa, and proteins from
the expanded constructs, CAG100 and CAA96, were detected at —85 kDa for both.
As for the transgenic flues with similar levels of expression, many observations were
made from Western blots. firstly, the polyglutamine expanded proteins (CAG92 and
CAA96) both migrated at their theoretical size of 55 kDa. Secondly, the presence of
other bands, most likely minor ataxin-3 isoforms, was also detected at —-60 kDa and —75
kDa. Thirdly, and more interestingly, extracts of the CAG92 expressing fly also
contained insoluble components which remained trapped in the stacking gel during SDS
PAGE. These trapped proteins most likely represent aggregates which are known to be
highly insoluble and migrate as high molecular weight complexes (Paulson et al., 1997b).
The insoluble components were also observed in the CAA96 fly extract, but at a much
lower level. The aggregates ofthe CAG92 extract most likely contain not only insoluble
polyglutamine proteins, but also non-polar, polyalanine proteins, as will be explained
later in Chapter 3. fourthly, in the CAG92 fly, an extra band appears at —40 kDa which
could possibly be a cleavage product of the polyglutamine protein. In the SCA3 mouse
mode! developed by Goti et al. (2004), a putative-cleavage fragment of 37 kDa was also
detected in the brains of the polyglutarnine expanded ataxin-3 transgenic mice. The
identification and characterization ofthis -.40 kDa hand will be performed in order to
confirm if it is indeed a cleavage product ofataxin-3 (Gaspar et al., manuscript in
preparation).
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figure 2.4 Expression ofataxin-3 protein from (A) lysates oftransiently transfected Cos-l ceils and (B) fly
beaU extracts. Shown are Western blots using ataxin-3 antibody. (A) Endogenous ataxin-3 protein was
detected at a size of—42 kDa along with the transfected full-length ataxin-3 EGfP-fused protein at --70 kDa
(CAG9), and expanded proteins at —$5 kDa (CAG 100 and CAA96). (B) Flies lack the functional homolog
ofataxin-3 and show only the size ofthe transgenic ataxin-3 construct at —55 kDa. Other minor ataxin-3
isoforms were also detected at —60 kDa and 75 kDa. The presence of insoluble mutant-ataxin-3 aggregates
(arrow) remained in the stacking gel in the fly extracts. A possible cleavage fragment (*) was also detected
in the CAG92 fly extract. Non-transfected (NT).
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2.5 Discussion
We have generated normal and expanded fifll-length constructs ofthe MJDJ cDNA and
successfully expressed them in Cos-1 celis to establish a cellular SCA3 model. With the
expanded MJDI constructs (CAG100 and CAA96), we were able to reproduce key
features of $CA3 disease, such as nuclear and cytoplasmic expression with the presence
ofintranuclear inclusions. In some ofthe CAG100-expressing ceils with very large
inclusions, we were also able to observe abnormal nuclear morphology, such as blebbing,
characteristic of apoptotic celis. Similar nuclear stress features were also detected by
Toulouse et aÏ., (2005), though necrotic morphology was also observed by Evert et al.,
(1999). These abnormal celis !ikely represent a later stage ofthe disease where the
inclusions become large and the cell is overwhelmed by their accumulation, thus
inducing an apoptotic response. In fact, recent evidence showed that full-length
polyglutamine-expanded ataxin-3 activates a mitochondrial apoptotic pathway and
induces neuronal death by promoting mitochondrial release of apoptogenic proteins (Tsai
et aÏ., 2004; Chou et al., 2006).
Our results are, however, comparable to a recently reported cellular mode!, which shows
that expression ofthe full-length ataxin-3 protein is !argely diffusely distributed within
the cells, irrespective ofthe polyglutamine length (Haacke et al., 2006). Aggregates in
this case were detected in 5-10% ofcells transfected with the polyglutamine expanded
ataxin-3 construct, which is a !ower frequency of aggregation than the one we obtained
here. it is important to re-emphasize the different cell types used (Cos-1 cells in this
study, mouse neuroblastoma celis (N2a) by Haacke et al. (2006), 293T cells by Perez et
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al., (1998), and HeLa by Chai et al., (1999a)) and slightly different constructs due to
epitope tags which likely contribute to observable differences.
Initial studies in the field daim that polyglutamine proteins must be proteolytically
cleaved in order to transiocate to the nucleus and exert their toxic effect (Zoghbi and Off,
1999). In keeping with this hypothesis, polyglutamine-containing fragments ofthe
ataxin-3 protein have been detected in neuronal inclusions in human brains ($chmidt et
al., 1998; Goti et al., 2004). Conversely, several other studies failed to detect any
proteolytic cleavage in SCA3 patient brains (Berke et al., 2004, Chou et al., 2006) or
transgenic mice models (Cemal et al., 2002). It is clear that a wide range of anti-ataxin-3
antibodies spanning the whole protein are required to determine if proteolytic cleavage
plays a role in SCA3 neurotoxicity. In vitro models of SCA3 have shown that at least
one caspase is able to release a polyglutamine-containing fragment from ataxin-3
(Wellington et al., 199$; Berke et al., 2004); however, a direct relationship in $CA3
between caspase cleavage of a polyglutamine protein and pathogenesis has yet to be
demonstrated in vivo for SCA3 (Zoghbi and Off, 1999). In another polyglutamine
disease, Huntington’s disease, the role ofa cleavage fragment in disease progression and
NI formation is also controversial. Studies showed that caspase-1 cleaves mutant and
wild-type huntingtin in vitro; further in vivo studies provide functional mechanistic
evidence ofcaspase-1 activation mediated by exon 1 of mutant huntingtin tOila et al.,
1999). Using dominant mutants ofcaspase-l, they observed that NI formation, specific
neuroreceptor abonormalities, and more importantly, symptomatic onset and mortality
was delayed, thus prolonging survival in their transgenic mouse model. As stated
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previously, the presence of a cleavage fragment in SCA3 and its implication in disease
progression is currently being investigated in our lab (Gaspar et al., manuscript in
preparation).
Most recently, Haaecke et al., (2006) demonstrated in a cellular model that the
introduction of a cleavage site into the full-length ataxin-3 protein increased the number
of aggregates and that this was also essential for the sequestration of full-length non
pathogenic ataxin-3. If proteolytic processing ofthe ataxin-3 protein occurs in our
system, the presence of an endogenous cleavage fragment could explain why we
observed a higher percentage ofcells with inclusions when compared to other studies.
Though this particular cleavage fragment could flot be detected by Western blot in our
cellular mode!, the finding by Haaecke et al. is in keeping with the potentially cleaved
ataxin-3 fragment in our fly model. Detection ofthis fragment in ccli culture could
simply be a matter of optimizing the conditions ofthe protein extraction procedure, as
was the case for detecting it in our fly model. On the other hand, the differences between
an in vivo and an in vitro system are many and obvious, which could explain any
discrepancies observed between the two systems.
In conclusion, although cellular models are versatile and practical for manipulation, they
do present drawbacks, especially in studies where massive overexpression ofthe mutant
proteins triggers celi death within days rather than years as seen in the patients.
Consequently, these models do not reproduce the processes leading to the slow advancing
dysfunction and degeneration ofneurons in the human diseases (Michalik and Van
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Broeckhoven, 2003), but rather provide insightful dues to certain aspects ofprotein
mechanisms and interactions. Thus, animal models are required to finely dissect the
rneclianisms ofpathology and to provide deeper insight into the disease. In mouse
models, for example, researchers were able to reproduce progressive neuronal
dysfunction, an occurrence which more closely and accurately mimics the human disease
than cellular models (Michalik and Van Broeckhoven, 2003). Despite the practical uses
ofmouse models in polyglutamine disorders, they too possess limitations as the same
mutant protein might flot lead to similar devastating phenotypes observed in patients.
Another limitation includes the lifespan ofthe mouse, which might flot be long enough to
complete the full cascade of changes that follows the initiating event (Gusella and
MacDonald, 2000). Nevertheless, all these models are valuable for investigating the
pathogenic triggers, as well as for identifying early biochemical targets, even if they may
not faithfully illustrate the final stages of celi death (Gusella and MacDonald, 2000).
As for Drosophila models of SCA3, such as the one we established, these are especially
important as they allow for the study ofthe gain-of-function hypothesis in
neurodegeneration, since invertebrates lack functional homologues of the protein in
question (Michalik and Van Broeckhoven, 2003). Drug screening in flics also lias its
advantages sucli as low cost, small size, short lifespan, and vast numbers of flics that can
be tested at the same time which is important for statistical analysis. This organism also
represents a rapid and inexpensive way to obtain pharmacological candidates for testing
in mamrnalian systems (Muqit and Feany, 2002). The best advantage ofDrosophila
models is its potential for large-scale screening methods through mutagenesis in order to
46
define novel gene activities that can modify the physiological effect of a toxic disease
protein in vivo (Fortini and Bonini, 2000). The benefits ofmodeling human diseases in a
fly model are relevant due to homologous cellular pathways which are involved in
pathogenesis in both organisms. For instance, we and others obtain a progressive
degenerative phenotype when we overexpress a foreign mutant human MJD] cDNA in
the fly; this demonstrates that the two organisms share common pathways and
mechanisms. However, caution should also be taken as flues might flot model pathology
in the same way as in humans due to activation of non-relevant pathways that are specific
to invertebrates (Muqit and feany, 2002). Nevertheless, Drosophila models are essential
for investigations on the mechanism of disease, and as such, have widely been used to
study several other neurodegenerative diseases.
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Chapter 3: The role of frameshifting in SCA3
3.1 Introduction: ribosomal frameshifting in SCA3
3.1.1 Simïlarities between SCA3 and OPMD
Pathological expansions of triplet repeats extend beyond polyglutamine-encoding CAG
repeats. Short expansions ofpolyalanine-encoding GCG repeats have been identified in
several genes, namely the poly(A)-binding nuclear protein 1 (PABPN1) gene, which
causes oculopharyngeal muscular dystrophy (OPMD) (Brais et aI., 1998). In fact, in this
particular disease, a very small polyalanine expansion is sufficient for protein aggregation
and toxicity (Brais et al., 1998). The presence of inclusions in both SCA3 and OPMD
led to the idea that they might share pathophysiological features. Both polyglutamine and
polyalanine inclusions are fonned similarly through aggregation of the misfolded protein
and formation of fibrillar macromolecules (Calado et al., 2000). Other similarities
between the two diseases include their late age of onset and specific ceil-type
degeneration despite widespread expression of mutant protein (Reddy and Housman,
1997; Ruegg et al., 2005). There is also the presence of ubiquitinated protein in the
aggregates and the involvement of chaperone and proteasome pathways in both cases
(Abu-Baker et al. 2003, Gaspar et al., 2000).
3.1.2 Previous studies on frameshîfting in SCA3
Based on the similarities between the two diseases, Gaspar et al., (2000) hypothesized
that a -1 ftameshift error could occur in the CAG tract ofMJD1 which would resuit in an
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altemate alanine-encoding GCA frame. The presence of frameshified polyalanine
species was indeed detected in lymphoblastoid celis and in the nuclear inclusions of
pontine neurons from MJD patients (Gaspar et aÏ., 2000). In addition to the in vivo
resuits, an in vitro mode! also showed that frameshifts did occur and that their frequency
increased with the size of the CAG repeat. furthermore, when replacing polyglutamine
repeats with polyalanine repeats in the same protein, toxicity increased.
A subsequent investigation was carried out by Toulouse et al., (2005) who found that
frameshifling was confined exclusively to the —1 frame and that it only occurred in
polyglutamine repeats encoded by a CAG codon. The authors showed that the
frameshifting enor occurs during translation and further evidence was also provided on
the increased toxicity of frameshifted polyalanine peptides.
3.1.3 Mechanism of programmed ribosomal frameshiftïng
The proposed mechanism of transiational errors in SCA3 is programmed ribosomal
frameshifting. In many viruses, this method is a common occurrence used by the
transiating ribosome to change reading frames in order to obtain several proteins from the
same mRNA (Harger et al., 2002).
The ribosome is a molecular machine which reads the open reading frame (ORF) ofthe
mRNA to faithfully and efficiently translate it into polypeptides. Non-standard coding
rnechanisms have also been identified: programmed ribosomal frameshifling can occur
where the transiating ribosome is induced to slide forward one nucleotide (+1 frameshifi)
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or backwards (-1 ftameshift). By doing so, multiple ORFs are utilized from the same
mRNA transcript (Shigemoto et al., 2001). Programmed -1 ribosomal frameshifing is
common to viral genomes and requires two basic sequence elements: a slippery heptamer
sequence and an mRNA structural element, such as a pseudoknot structure or a stem-Ioop
downstream from the slippery sequence (Shigemoto et al., 2001). The ‘simultaneous
stippage mode!’ proposes that the repetitive nature ofthe first cis-acting mRNA signa!,
the ‘slippery sequence’, allows for the ribosome-bound tRNAs to realign in the -1 frame
(Jacks et aÏ., 1988). The second element, the mRNA secondary structure, interacts with
the ribosome and causes the ribosome to pause over the slippery sequence. This stalled
complex is associated with a helicase which attempts to unwind the secondary structure,
but is stereochemically unable to do so. As a resuit, strain is placed on the tRNA
coimected to the ribosome resulting in breakage of codon-anticodon interaction. As the
tRNA structure is relaxed, it is alÏowed to re-pair with the mRNA, but this time in the -1
position (Namy et al., 2006). Other cis-acting factors important to frameshifiing include
the spacing between the slippery sequence and secondary structure (Farabaugh, 1996).
Though investigations of the mechanism of frameshifling were based on viral models,
cases have also been identified in mammalian genes which also use -1 programmed
ribosomal frameshifting (Shigemoto et al., 2001).
Another type of -1 frarneshifling can also occur in the absence ofthe slippery sequence.
This ‘hungry codon’ hypothesis requires special structural features of some tRNAs, such
as doublet decoding (the recognition of a 2-base codon by a 2-base anticodon), that allow
them to promote disruption of the reading frame. This type of decoding might occur as a
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resuit of depletion ofparticular aminoacyl-tRNAs in celis starved of a particular amino
acid (Farabaugh, 1996). It was also shown that the nature ofthe downstream secondary
structure couid also act to increase frameshifling in response to aminoacyl-tRNA
limitations (Atkinson et al., 1997).
Though it is not known which of these frameshifiing mechanisms occurs in SCA3
affected celis, the expanded CAG repeat is known to form long stable hairpin structures
in the transcript, meeting the secondary structure requirement in both cases (Michlewski
and Krzyzosiak, 2004).
3.1.4 Frameshifting in a fuII-Iength context
As mentioned earlier, frameshifling was identified as a contributor to pathogenesis of
SCA3 in other models, but ail studies so far were performed using a truncated version of
the mutant protein (Toulouse et al., 2005). Though it is known that truncated mutant
proteins containing the polyglutamine tract are more toxic to neurons and peripheral
celis, it is also important to note that the typical graduai centrai nervous system pathology
in these diseases is oniy seen when fuii-length proteins are expressed. Therefore, the
specific protein context of each mutant protein also contributes to the late onset of
polyglutamine diseases and selective neuronal vulnerability (Zoghbi and Orr, 2000).
Evidence lias shown that the unique protein composition of each expanded polyglutamine
protein plays an important role in specifying the details ofthe pathogenesis, as studies
using polyglutamine proteins in the absence of normal protein context are flot able to
replicate the specific features ofdisease (Chai et al., 2001). In particuiar, the
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composition ofnuclear inclusions differs depending on the protein context ofthe
expanded polygltutamine domain (Chai et al., 2001).
Additionally, resuits have shown that full-length ataxin-3 proteins were much less
efficient at forming aggregates than did C-terminal ataxin-3 fragments with an extended
polyglutamine segment, which empliasizes the influence of the full-length sequence
context on the aggregation properties of ataxin-3 (Haacke et aÏ., 2006). Therefore, it is
important for future studies to examine frameshifting in a fuII-length context in order to
fully understand its contribution to the progression ofthe disease.
32 Objective
In the second part ofthis study, the objective is to confirm that ribosomal frameshifting
does occur using the established full-length ataxin-3 cellular mode! in an attempt to
elucidate its contribution to SCA3 pathogenesis.
3.3 Materials and Methods
3.3.1 Immunocytochemistry
Cells were seeded the day before at a density of 150,000 cells per well on coverslips in 6-
well plates. Forty-eight hours afler transfection, celis were washed in PBS, fixed for 15
min in 4% paraformaldehyde, washed twice in PBS, permeabilized with 0.2% Triton X-
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100 PBS, washed twice in PBS, and blocked for 1 hr with 10% normal goat serum
(NGS). The primary antibody (Rabbit anti-HA epitope/fusion tag antibody (Alpha
Diagnostic International)) was diluted 1:500 in 2% NGS and incubated at 37°C for 30
min before use. Coverslips were then incubated with the diluted primary antibody at
room temperature overnight. The secondary antibody (Rhodamine (TRITC)-conj ugated
AffiniPure Goat Anti-Rabbit IgG, Fragment Specific (Jackson ImmunoResearch
Laboratories)) was diluted 1:300 in 2% NGS and incubated at 37°C for 30 min before
use. Afler washing coverslips three times in PBS, they were incubated in the
corresponding diluted secondary antibodies for 1 hr. Celis were washed 5 times in PBS
and mounted using DAPI Mounting Medium for F luorescence (Vector Laboratories).
Ceils were viewed by using fluorescence microscopy (Leica DM6000) under 400x
magnification. The digitally stored images were combined and displayed using OpenLab
software and assembled using Adobe Photoshop 8.0.
3.3.2 Quantification of frameshifting
b quantitate frameshifling, we scored ail celis that were EGFP and HA-positive in five
random microscope fields at 200x magnification. Data are expressed as the percentage of
cells with frameshifted proteins (HA-positive) over transfected celis (EGFP-positive).
3.33 Statistical analysis
Analysis on frequency of frameshifting was carried out using the One-way Anova of
variance test.
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3.4 Results
3.4.1 Generation of a cellular frameshifting reporter system
In order to further understand frarneshifling within large CAG repeats, we used the full
length MJD 1 constructs generated in Chapter 2 of this study in a cellular model as a
ftameshifting reporter system. In order to do so, we made use ofthe epiptope tags at the
C-terminus of each construct. Three epitopes were present on ail constructs and were
specific for each reading frame: a Myc epitope in the main frame (polyglutamine), an HA
epitope in the —1 frameshifted reading frame (polyalanine), and a His-tag epitope in the
+1 frameshifted reading frame (polyserine) (Figure 2.1). It was ensured that a translation
initiation site was present only in the main frame so that initiation couÏd not occur in any
of the other reading frames. As mentioned earlier, the two CAG repeat lengths were:
CAG9 (wild-type) or CAG100 (expanded polyglutamine). In both ofthese cases, if
frameshifting to the —1 frame occurs, the ribosome would shifi to read a GCA repeat
which codes for alanine proteins. The third constmct, CAA96, also codes for expanded
polyglutamine, but it differs from the CAG1 00 construct in that if ftameshifting were to
occur into the —1 frame, the ribosome would instead read an ACA repeat which codes for
threonine.
3.4.2 Detection of frameshifting in a cellular model
The described constructs were transfected into Cos-1 celis and monitored through
immunocytochemistry performed using an antibody against the —1 frame (anti-HA
epitope). Frameshifiing was monitored at 48 hrs post-transfection since it was reported to
peak during this period when using the truncated form of ataxin-3 (Toulouse et aÏ., 2005).
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Since the constructs express EGFP in the main frame, expression of the main frame
ataxin-3 protein could be observed directly under fluorescent illumination.
The presence of—1 frameshified HA-positive species was observed only in celis with
polyglutamine inclusions (CAG100 and CAA96) and flot in the wild-type MJD1
construct (CAG9) (Figure 3.1). These frameshified polyalanine species in the CAG100-
transfected celis were expressed as smail aggregates which were localized perinuclearly
and cytoplasmically and did flot completely co-localize with the polygiutamine
inclusions. As expected, cells expressing only the -1 frameshifted species were neyer
observed. Though ftameshifting to the +1 frame was not examined in this study, it had
neyer been observed in other studies (Toulouse et al., 2005).
It was also observed that the nuclear morphology of CAG1 00 transfected ceils which
contained polyaianine species was irregular compared to polyalanine-lacldng ceils. As
for the CAA96 transfected ceils, which cannot frameshift into alanine-containing
proteins, the nuclear morphoÏogy did not display irregularities and was indistinguishable
from the CAG9 transfected celis. Therefore, as nuclear morphoiogy is an indication of
toxicity, it appears that the production of polyaianine proteins through frameshifiing
might contribute to cellular toxicity.
3.4.3 Frequency of -1 frameshifting in ceils
As not ail celis expressing the expanded polyglutamine protein dispiayed frameshified
ataxin-3 molecules, it was important to establish the frequency of its occurence in order
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to determine what the contribution to toxicity might be. In order to determine how
frequently frameshifting occurs in the different constructs, transfected ceils were counted
from several random fields and scored for the presence of HA staining. The ftequency of
ribosomaÏ frameshifiing, or siippage, was calculated as the number of HA positive celis
over the number ofcells transfected (figure 3.2). 0f the transfected celis, 18.1% of
CAG100 and 3.8% ofCAA96 expressing celis were positive for the HA staining. Using
the One-way ANOVA test of variance, the resuits show that the difference between the
frequencies ofribosomal siippage observed in the CAG100 construct and CAA96 is
highly significant. f(1,20) = 8.47 (P<O.O1). Moreover, no significant difference was
visible when comparing celis expressing CAG9 with celis expressing CAÀ96.
Therefore, it was confirmed that when using the full-length MJD1 construct,
frameshifting does not occur with normal CAG repeat lengths (CAG9). It only occurs
significantly with expanded CAG repeat tracts (CAG100) and not with CAA repeat tracts
(CAA96). These resuits are in accordance with those obtained by Toulouse et al., (2005),
who also demonstrated using a truncated ataxin-3 construct that expanded-CAG repeats
frameshifted significantly more than expanded-CAA repeats.
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Figure 3.2 Frequency ofribosomat siippage to the —1 frame generating polyalanine proteins occurs
significantly more in the CAG 100 than in the CAA96 construct. Ce!! count from immunocytochemistry on
transient!y transfected Cos-1 celis 48h post-transfection. frequency ofsiippage was calculated as number
ofpolyalanine expressing ceits (HA-positive) over number oftransfected cet!s (EGFP-positive). Resuits
are presented as the mean offive fie!ds counted ± SE.
Figure 3.1 frameshifted po!yalanine products are detected in CAG 100. Immunocytochemistry on
transiently transfected Cos-1 ceils with wild-type (CAG9), expanded MJDI (CAG 100), and expanded
MJD Y (CAA96) constructs. The presence of -1 frameshifted species was detected by HA-antibody.
Nuclear staining was done using DAPI.
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3.5 Discussion
In this section of the study, we used the full-length ataxin-3 ceil mode! established in
chapter 2 and were able to confirm that ribosomal s!ippage to the —1 frame does occur
within the SCA3 CAG repeats to produce polyalanine proteins. The presence ofthe
polyalanine species in perinuclear and cytoplasmic regions suggests that the proteasome
degradation pathway might be overwhelmed and that the celi succumbs to the
poÏyalanine toxicity. This phenomenon is specific only to the expanded CAG construct
as it does flot occur at a significant level in the expanded CAA construct and it is
undetectable with the short CAG construct.
Despite clear!y being ab!e to detect the presence of frameshifted polyalanine proteins by
immunocytochemistry, the task of quantifying its presence by Western blot analysis
remains elusive in this study. Thougli it lias been detected in one celi culture model
(Toulouse et al., 2005), the reported study used a trnncated ataxin-3 construct in which
frameshifting occurs at a much higher ftequency (47% of ceils). full-length ataxin-3
proteins do not frameshift as often, leading to lower !evels ofpolya!anine species content
and perhaps !ending to the difficu!ty in detection by immunoblotting we have
experienced. Other explanations include difficulty in extraction of the insoluble
polyalarnne species, which might require more stringent extraction conditions (currently
underway in our lab).
The reason why frameshifiing does flot occur to a large extent in CAA96, when
compared to CAG100, is most !ikely due to the nature ofthe mRNA and its secondary
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conformation. Secondary structure and energy requirement analysis comparing the two
repeats show that oniy the CAG repeat forms stable hairpins, whereas the CAA repeat
forms a single large ioop (Toulouse et al., 2005). Therefore, only in the presence of an
expanded CAG repeat would the ribosome be stalled and induced to frameshift to the -1
frame.
(CAG)78 (CAA)73
Figure 3.3 Secondary structure predictions for polyglutamine encodmg repeats. Only the mRNA of long
CAG repeats forms a hairpin whereas the CAA repeats only forms a large single ioop, as predicted by the
MFOLD program. Toulouse et al., (2005) Hum Mol Genet. 14(l$):2649-60.
Although the frequency of frameshifting with a normal CAG length (less than 40) was
reported to be 0.7% ofthe total population ofcells, or 5% oftransfected celis, in other
studies (Toulouse et al., 2005), in our current model, frameshifiing was not detected at ail
in the wild-type construct. Furthermore, when using the truncated version in the previous
study, frameshifling occurred in a greater fraction of celis with the expanded CAG
construct by comparison to expressing the full-length version (47% vs. 18%,
respectively). This was to be expected, as truncation of the protein appears to produce
toxic effects faster than when the polyglutamine domain is flanked by the entire protein
(Ikeda et al., 1996). Aiso, it was shown that in the Drosophila model developed by
Warrick et aÏ., (2005), the ataxin-3 wiid-type protein bas an intrinsic protective role in
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polyglutamine toxicity. In this study, when a normal full-length ataxin-3 protein was co
expressed with a pathogenic full-length ataxin-3 protein in the fly eye, these transgenic
flues showed dramatically improved retinal structure and retained vision in comparison to
flues bearing the pathogenic allele atone, which showed degeneration ofthe eye and were
blind. Furthermore, the restoration ofthe eye phenotype mediated by normal ataxin-3
protein was attributed to a delay in nuclear inclusion formation by the pathogenic protein
and was dependent on the normal protein’s ubiquitin-associated activities. From what
was shown by this group, we can conciude that in the absence of ail the functional
domains of the ataxin-3 protein, it would not be possible to assess its protective role in
mediating disease progression, which couid reduce or delay the occurrence of
frameshifting in our case into the more toxic polyalanine frame.
The contribution of frameshiffing to toxicity was inferred by examining the nuclear
morphology of affected ceils. Only the expanded-CAG repeat induced an abnormal
nuclear morphology that suggests ceÏ!s are undergoing apoptosis. The expanded-CAA
nuclear morphology was comparable to the normal CAG repeat. These resuits also
correlate with what we observed in our Drosophila mode! (from chapter 2), where celi
toxicity in the eye was seen only in the CAG92 and not the CAA96-expressing flues,
which were indistinguishable from control flues. Our previous studies oftoxicity used
inducible stable transfectants, light scattering properties ofcells, and propidium iodide
staining to quantify cell toxicity. Though they were performed using a truncated version
of the ataxin-3 protein, these studies showed that there was an increase in ce!! death over
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time in both expanded polyglutamine constructs, but more notably in the expanded-CAG
construct due to the presence ofpolyalanine proteins (Toulouse et al., 2005).
Polyalanine polypeptides are known to be toxic. Polyalanine peptides form t3-pleated
sheet fibrillar macromolecules (Blondelle et aï., 1997) and these stable oligomers are
extremely resistant to chemical denaturation and enzyrnatic degradation (Forood et al.,
1995). Physiological evidence for this toxicity includes the presence of the PABPN1
mutant protein in inclusions which are also more resistant to salt extraction (Calado et al.,
2000). Other studies have shown that polyalanine aggregates are associated with toxicity
and ceil death (Rankin et aÏ., 2000).
As for polyalanine toxicity in comparison to polyglutamine, there are important
differences which must be considered to fiully understand their respective involvement in
the disease process. It is likely that polyalanine and polyglutamine expansions interact
witli different subsets ofproteins due to different chemical properties, since glutamine is
a polar amino acid and alanine is a non-polar amino acid (Rankin et al., 2000).
Aggregates of expanded ataxin-3 have previously been shown to be of fibrillar form
(Chow et al., 2004). Similarly, aggregates ofpolyglutamine expanded ataxin-7 were also
fibrillar, but in contrast, when its polyglutamine tract was replaced by a polyalanine tract,
researchers observed small, numerous, insoluble microaggregates rather than a few large
structured aggregates of soluble polyglutamine proteins (Latouche et aï., 2006) which
correlate with what we observed here with the HA staining in expanded-CAG constructs.
Furthermore, the constnicts expressing the polyalanine tau led to significantly greater
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neuronal loss than polyglutamine containing constructs ofthe same protein (Latouche et
al., 2006). This provides further evidence ofthe way these proteins containing alanine
polymers accumulate and the resulting toxicity ofpolyalanine aggregates.
Therefore, all these combined reports, together with our resuits, provide strong evidence
pointing towards the increased toxicity ofpolyalanines over polyglutamines (Rankin et
al., 2000; Gaspar et al., 2000; Toulouse et al., 2005; Latouche et aï., 2006). In a recent
study investigating the toxicity ofpolyalanines, researchers found that at high doses,
polyalanines were indeed harmful to ceils; surprisingly, however, at low doses
polyalanines could protect against polyglutamine toxicity (Berger et al., 2006). This
group generated transgenic flues expressing either short (normal) or long (pathogenic)
polyalanines fused to a nuclear Ïocalization signal. When the pathogenic transgene was
expressed in the nervous system, they observed abnormal behaviour manifestations and
reduced survival to adulthood in comparison to normal flues. And, when the pathogenic
transgene was expressed in the eye, they observed an abnormal eye phenotype which was
associated with inclusion formation, thus verifying the toxic effects ofpolyalanines. On
the other hand, the effect ofpolyalanines at Ïow doses was shown to be protective against
polyglutamine toxicity. When this same group used a celi model to co-transfected a
pathogenic polyalanine peptide at a low dose with an N-terminal fragment of the
huntingtin protein (the mutant protein in Huntington’s disease) containing a pathogenic
length ofpolyglutamines, they observed a decreased toxicity accompanied by a decrease
in inclusion formation. This protective, anti-apoptotic effect was mediated by induction
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of a heat-shock response by polyalanine. Their resuits were also confirmed in vivo in a
Drosophila model (Berger et al., 2006).
Further detailed investigations of our cellular model would be required to determine the
level ofpolyalanine expression in frameshifled celis that also contain polyglutamine
proteins, in order to test whether this protective effect is also present in SCA3. It would
be difficult to relate this effect to SCA3 patient brain tissue as the amount ofpolyalanine
proteins in affected neurons would be difficult to quantify in order to compare its toxicity
at low and high doses. Nevertheless, this polyalanine protective effect investigated by
Berger et al., appears to be independent ofthe protein context and could add to the
previously reported protective effect of normal ataxin-3 (Warrick et al., 2005).
In conclusion, we developed a system to investigate a unique aspect ofthe pathology of
SCA3 and possibly other CAG-repeat diseases. In light ofthe evidence showing
differences in disease manifestations in a full-length protein context, this new cellular
frameshifting model should more accurately represent cellular processes in the disease
progression; furthermore, it will be used to explore potential therapeutic treatments.
Likewise, our SCA3 fly model (mentioned in Chapter 2), also generated using the full
length gene tagged in three frames, is currently being used to investigate the contribution
of frameshifting to disease developement in a living organism (Gaspar et al., manuscript
in preparation). This in vivo model will complement well what we have shown in the
cellular model presented here in an attempt to understand the pathogenesis of SCA3 in
humans.
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Chapter 4: Transcriptïonal dysregulation in
polyglutamine disorders
4.1 Introduction: the study of transcriptïonal impairment
4.1.1 Sequestration of transcriptional activators by inclusions
An early component ofpolyglutamine toxicity appears to be altered gene expression at
the transcriptional level. in order to discem the mechanisms by which this process might
occur, researchers have looked into factors involved in transcriptional activity. The study
oftranscriptional regulator involvement in polyglutamine diseases has mainly focused on
celiular proteins which possess glutamine repeats, as these domains wouid be prone to
forming homotypic glutamine-glutamine interactions with the pathogenic polygiutamine
repeats (Michalik and Van Broeckhoven, 2003). Due to the nuclear localization ofboth
transcription factors and mutant polygiutamine proteins, there is heightened interest in
identifying aberrant interactions between these two types ofproteins (Chai et al., 2001).
Examples of glutamine-rich transcriptionai regulators include cAMP-response element
binding protein (CBP), TATA-binding protein (TBP), TBP-associated factors
(TAF11 130), and Specificity protein 1 (Spi); these have ail been identified as factors
which interact directly with mutant polyglutamine proteins and are sequestered into
inclusions in cellular and animal models ofthese diseases, and in patients’ tissue
(Michalik and Van Broeckhoven, 2003). Consequently, the suppression of functional
activity ofthese elements couid repress transcription and contribute to pathogenesis
(McCampbell et al., 2000). Though it is possible that depletion ofthese nuclear factors
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from the nuclear matrix could attenuate transcription, there is also reason to believe it
might flot be the sole cause ofthis observation. For example, the lack ofhistone
acetyltransferase activity by CBP could be supplemented by any ofthe other coactivators
with the same activity (Okazawa et al., 2003). Also, some types of inclusion bodies
(such as those in SCA3) are dynamic and allow for import and export ofproteins, which
suggests that nuclear proteins are not permanently sequestered in inclusions (Chai et al.,
2002). Therefore, in light ofthese observations, the sequestration hypothesis may require
further revision in order to explain transcriptional repression by inclusions.
4.1.2 Inhibition of histone acetyltransferase activity
Another mechanism oftranscriptional dysfunction involves harmful interactions between
the expanded polyglutamine tracts and the acetyltransferase domains of several histone
acetylases, such as CBP, p300, and P/CAF (Steffan et al., 2001). As these enzymes are
responsible for the acetylation ofhistones, they function to maintain chromatin in a
transcriptionally active state. Impairment oftheir actions thereby compromises
transcription and contributes to polyglutamine pathogenesis. As further proof,
researchers have successfully shown that by blocking the action ofhistone deacetylases,
thereby increasing acetylation ofhistones, neurodegeneration can be reduced in
DrosophiÏa and cellular models ofpolyglutamine toxicity (McCampbelÏ et al., 2001;
Steffan et al., 2001). Thus, the decrease in histone acetylation could be a common
rnechanism oftranscriptional repression in polyglutamine disorders.
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4.1.3 Direct co-repressor activity
An additional mode of transcription dysregulation in expanded CAG disorders could be
mediated by the mutated protein in question. It has been found that several ofthe
polyglutamine disease proteins can ffinction directly to repress transcriptional activity.
For example, in SCA1, the AXH domain of the wild-type ataxin-i protein is responsible
for transcriptional repression and participates in protein aggregation (de Chiara et al.,
2005). Another example includes atrophin-i, the mutant protein in DRPLA, which also
lias the role ofrepressing transcription as part ofits normal function (Wood et al., 2000).
Therefore, perturbations of the normal function of these mutant proteins would suggest
that altered transcription may be a major cause of celluiar dysfunction in polygiutamine
diseases.
4.1.4 Transcrïptional impairment factors in SCA3
As for SCA3, a multitude oftranscriptional changes are to be expected in the presence of
mutant ataxin-3 protein, not only through aberrant interactions with important
transcription factors, but also through loss of normal transcriptionai regulator activity of
the protein.
Firstly, transcription factors, especialÏy those containing a glutamine domain, have been
shown to be recruited to inclusions and therefore could impair transcription due to a
suppression of their normal activity. Transcription factors that have been studied in
SCA3 and are believed to be involved in cellular dysfunction in this disorder include
TBP, TAF1113O, Spi, CREB and CBP (Yamada et al., 2000); these have ail been found to
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co-localize with nuclear inclusions in SCA3 brain tissue (Shimohata et al., 2000). In the
case ofthe transcription activator CBP, it is known to be implicated in neuronal
responses to nerve growth factors (Liu et al., 1998); the lack ofits functional activity
probably diminishes its ability to mediate signais critical for neuronal survival
(McCampbell et al., 2000). These results suggest that nuclear depletion of essential
transcription factors containing a glutamine-repeat domain could be the cause for
neurodegeneration in affected celis.
This glutamine-specific sequestration even seems to be the case in invertebrate models.
In Drosophila, eyes absent (EYA) protein is a transcriptional activator important in eye
development, but more importantly it contains a polyglutamine tract near the N-terminus
(Bonini et al., 1993). By virtue ofthis poiyglutamine domain, it too is recruited into
nuclear inclusions (Perez et al., 1998).
On the other hand, transcription factors lacking a polyglutamine domain are also
recruited to inclusions. Transcriptional activators or co-activators MAML1 (Chai et al.,
2001), and PML (Yamada et al., 200 lb) ail appear to be targeted to long polyglutamine
tracts of ataxin-3 and are recruited to inclusions.
Secondly, transcriptional impairment is beiieved to be involved in SCA3, since aitered
expression of several genes is observed in the presence of mutant ataxin-3 protein. Gene
profiling of mutant ataxin-3 expressing ceils and SCA3 patient brain tissue shows
differentially expressed genes invoived in the inflammatory reactions, nuclear
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transcription, and ceil surface-associated processes (Evert et al., 2003). Expanded ataxin
3 protein also causes transcriptional dysregulation ofapoptotic factors Bax and Bcl-XLby
either direct interaction with transcription factors or through sequestration of crucial
transcription factors linked to these apoptotic molecules, thus inducing neuronal ce!!
death in SCA3 (Chou et al., 2006). It is flot known, however, whether these observed
changes occur due to the presence ofthe mutant protein, or if they simply reflect
consequences ofthe pathogenesis.
Finally, direct repressor activity by the mutant protein could also bring about $CA3
pathoïogy. As mentioned earlier, ataxin-3 is a histone-binding protein with two
independent co-repressor activities (Li et al., 2002). Any perturbation ofits endogenous
function could lead to transcriptiona! impairment.
4.1.5 Transcriptional impairment through altered RNA polymerase II
function
RNA polymerase II (RNAPII) is the central enzyme responsible for generating mRNA
transcripts. As it is a critical mo!ecule for transcription, any disturbance ofits function
would be predicted to altered gene expression. The functiona! activity ofRNAPII is of
interest since it can be affected by ce!!u!ar stress, such as in the presence ofmisfolded
proteins and inclusions. Nuclear factors which bind to polyglutamine disease proteins
and are shown to interact with RNAPII include polyglutamine binding protein-1 (PQBP
1), CA15O, ‘suwival ofmotor fleurons’ protein (SMN), CBP, and TBP (Okazawa, 2003);
the last two ofwhich have been shown to be sequestered in SCA3 inclusions. Studies in
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other polyglutamine diseases, such as SCA1 and Huntington’s disease, have reported
altered activity of the RNAPII (Okazawa et al., 2002; Luth-Carter et al., 2002). Though
it is flot known by which mechanism the function ofRNAPII is affected in SCA1 and
Huntington’s disease, it is quite possible that it could be one shared by other
poyg1utamine diseases and, therefore, there is good reason to believe that RNAPII could
be involved in SCA3 pathology as well.
4.1.6 Structure and function of RNAPII
The human RNAPII is composed of 12 subunits (Kersimar et al., 199$). The largest
subunit of the mammalian RNA polymerase II consists of a C-terminal domain (CTD)
which is comprised of an evolutionarily conserved consensus sequence, Tyr-Ser-Pro-Thr
Ser-Pro-Ser (YSPTSPS) (Corden, 1990). The number of repeats varies depending on the
species: 20 in yeast, 45 in flues and 52 in mammals (Palancade and Bensaude, 2003).
Five ofthe seven amino acids ofthe consensus sequence can be phosphorylated (Jones et
al., 2004) and phosphorylation correlates with the level ofactivity ofthe polymerase:
initiating polymerases are hypophosphorylated (ho), whereas elongating polymerases are
hypherphosphorylated (“A) (Cadena and Dahmus, 1987; Payne et al., 1989).
Phosphorylation pattems differ during the transcriptional process: Ser5 phosphorylation
is associated with the promoter at initiation, whereas Ser2 phosphorylation is associated
with elongation in the coding region (Kormanitsky et al., 2000). The kinases responsible
for phosphorylation include CDK9/cyclin Ti (pTEFb), which phosphorylates Ser 2
(Marshall and Price, 1995), and CDK7/cyclinWMATl, which phosphorylates SerS
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(Rodriguez et al., 2000; Schroeder et al., 2000). Their actions are opposed by the
following phosphatases: TFIfF-associated CTD phosphatase (fcpl), Ssu72, type 1
protein phosphatases (Ppl), and small CTD phosphatase (Scpl) (Yeo et al., 2003;
Palancade and Bensaude, 2003).
In addition to regulating transcription, CTD phosphorylation also mediates binding
partners involved in mRNA processing steps (Proudfoot et al., 2002). CTD
phosphorylation is important in mRNA synthesis as Ser5 phosphorylation mediates
recruitment and activation ofthe 5’ capping enzyme and promoter clearance (Ho and
Shuman, 1999), and $er2 phosphorylation is involved in recruitment of 3 ‘RNA
processing factors and efficient 3’ cleavage and polyadenyÏation (Ahn et al., 2004; Ni et
al., 2004). Another role for phosphorylation ofthis domain is to recruit chromatin
modifying enzymes (Palancade and Bensaude, 2003).
The RNAPII phosphoisoforms
“A and 110 co-exist in dynamic equilibrium, regardless of
transcriptional state ofthe celi (Palancade and Bensaude, 2003). In conditions ofcellular
stress, such as exposure to toxins or UV radiation, the levels ofRNAPIT in the
hyperphosphorylated form increase (Palancade and Bensaude, 2003), most likely to
augment transcription of essential survival genes. As polyglutamine toxicity is associated
with cellular stress and transcriptional disturbances, we sought to investigate RNAPII’s
functional activity through its phosphorylation level in affected SCA3 celis.
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4.2 Objective
The third objective ofthis study is to determine if transcriptional dysregulation by
RNAPII plays a role in $CA3 using both the estabiished ceilular and the Drosophila
model.
4.3 Materials and Methods
4.3.1 Immunocytochemistry
Immunocytochemistry was performed as previously described in Cos-1 celis transfected
with ail tbree constructs. The primary antibody used for immunocytochemistry was RNA
polymerase II H5 monoclonai antibody (1:500) (Covance Research Products) with the
secondary antibody Alexa Flor 488 donkey anti-mouse (1:300) (Molecuiar Probes).
4.3.2 Quantification of inclusions
To quantitate the expression ofphosphorylated RNAPII, we counted ail transfected celis
that were positive for H5 staining in six random microscope fieids at 200x magnification.
Data are expressed as the percentage of transfected ceils with H5 expression.
4.3.3 Statistical analysis
Analysis ofthe frequency of phosphorylated RNAPII expression in celis was performed
using the One-way Anova of variance test.
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4.3.4 Protein extraction and Western blot analysis
Forty-eight hours after transfection, Cos-1 and HeLa ceils transfected with ail three
constructs were harvested the same as described in chapter 2. Western blots were also
performed same as previously described in chapter 2, except membranes were blocked
and antibodies diluted in 5% BSA (Fisher Scientific) in PB$-T (0.1% Tween-20 in PB$).
The primary antibodies used in this section were Polyclonal RNA polymerase II CTD
repeat YSPTSPS (phospho S2) antibody (1:1000) (abcam), Purified mouse anti-RNA
polymerase II monoclonal antibody [CTD4H8](1 :1000) (BD Biosciences), and Mouse
anti-actin monoclonal antibody (1:10 000) (Chemicon International). The secondary
antibodies used were Peroxidase-conjugated AffiniPure Goat Anti-Rabbit IgG (1:10000)
(Jackson lnimunoResearch Laboratories) for the first primary antibody and Anti-mouse
IgG HRP-linked antibody (1:10 000)(Cell Signaling Teclmology) for the other primary
antibodies.
4.4 Results
4.4.1 Expression of phosphorylated RNAPII in ceNs
Irnmunocytochemistry was carried out using the monoclonal H5 antibody, which is
specific for the hyperphosphorylated form ofRNAPII at Ser2, but is also known to bind
at Ser5 phosphorylation site (Jones et al., 2004). This antibody was used to detect the
presence ofRNAPII molecules engaged in active mRNA synthesis (Palancade and
Bensaude, 2003). Expression of phosphorylated RNAPII occurs throughout the nucleus
with larger punctuated nuclear structures that match transcription foci (figure 4.1). It has
72
been reported that these ‘dots’ overlapped with bromouridine incorporation, indicating
that they represent active sites of in situ transcription (Zeng et al., 1997). In our system,
staining ofH5 in ail three constructs - normal (CAG9) and expanded forms (CAG100 and
CAA96)
- ail showed similar expression pattems. In an attempt to determine if the
number of cells which expressed phosphorylated-RNAPII differed between the
constructs, the total number oftransfected ceiis were counted from several fields and
scored for positive H5 expression; however, resuits showed that they did not significantly
differ (Table 4.1). As for nuclear inclusions present in the expanded forms, they rarely
co-iocalized with the transcription foci, indicating that hyperphosphorylated RNAPII is
not recruited to the inclusions.
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Figure 4.1 Detection ofphosphorylated RNA polymerase II by H5-antibody (orange) by
immunocytochemistry on transiently transfected Cos-l celis. H5 staining shows nuclear distribution with
punctuated transcriptional foci (arrows in I-15) which do not co-localized with nuclear inclusions (arrows in
EGfP) (green). DAPI staining ofnuclei (blue) is shown in the third column of panels and the last column
of panels show merged images ofEGfP, H5, and DAPI staining.
Table 4.1 Percentage oftransfected ceits with phosphorylated RNAPII expression.
Construet Percentage of transfected cetis (%)
CAG9 69.3
CAG100 48.9
CAA96 46.9
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4.4.2 Quantifïcation of RNAPII phosphorylation at the protein level
Western blot analysis was performed on Cos-1 and HeLa ceils transfected with the three
constructs described previously using a polyclonal antibody against the phosphorylated
Ser2 ofthe CTD repeat ofthe RNAPTI (PS2) and another monoclonal antibody against
both the hyper- and hypophosphorylated Ser5 form ofthe CTD repeat (CTD4H8) (Figure
4.2). The resuits with the PS2 antibody show that in both cdl unes there is no noticeable
difference in the levels of expression of activated form of RNAPII in the mutant ataxin-3
construct (CAG100) compared to the others. The same results were produced using the
Ser5 specific antibody (CTD4H8). In this case, the higher molecular weight band (ho)
represents the hyperphosphorylated form at 240 kDa, while the smaller band (lIA)
represents the hypophosphorylated form at 210 kDa. There does not appear to be any
shifi between the two “A to 110 forms in either constructs.
Using the same two antibodies on Western blots obtained from our transgenic fly model,
similar resuits were obtained. Both transgenic flues (CAG92 and CAA96), as well as the
control fly, showed the same level ofphosphorylated RNAPII expression. Therefore,
since we do flot see a difference in the phosphorylation state between wild-type and
mutants, we do flot have reason to believe that the functional activity of RNAPII is
compromised in SCA3.
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Figure 4.2 Phosphoiylated RNA polymerase II protein levels do flot show differential expression in
mutants. Western blot on transiently fransfected Cos- 1 cells (A, D), HeLa cetis (3, E), and transgenic flues
(C, F). The PS2 antibody recognizes the phospho-Ser 2 ofthe CTD consensus sequence, YSPTSPS; the
CTD4H8 antibody recognizes both the hypophosphorylated (liA) and hyperphosphorylated (1I) foi-m at
position Ser 5 ofthe CTD repeat. Non-transfected (NT).
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4.5 Discussion
In this chapter ofthe study, we sought to investigate a functional link between SCA3 and
altered transcription. In particular, we investigated transcriptional dysregulation as a
mechanism ofpathology by specifically analyzing RNAPII function. We investigated the
activity of RNAPII by using antibodies specific for the two main phosphorylation sites on
the serine residues. Our resuits show that neither the active RNAPII is recruited to
nuclear inclusions formed by the mutant protein, nor is the level ofphosphorylation of
RNAPII affected in our polyglutamine mutants. Therefore, we do not believe that the
transcriptional activity of the enzyme is impaired in the presence of mutant ataxin-3
protein. Though resuits from some studies suggest that the level ofphosphorylation may
not correlate exactly with transcriptional activity, it is known that hyperphosphorylation
occurs together with initiation of transcription and the elongating RNAPII (Zeng et al.,
1997).
Reports in other polyglutamine diseases such as SCA1 have found that a ternary complex
containing mutant ataxin-l and PQBP-1 did flot sequester RNAPII into inclusion bodies,
but did reduce levels ofthe active species (Okazawa et al., 2002). In that study, since the
RNAPII was also not sequestered to inclusion bodies, it was suggested that the pathology
could be mediated by the soluble and flot the inclusion-forming fraction of the mutant
polyglutamine protein. By Western blot analysis, the authors observed a decrease of
phosphorylated RNAPII in ceils which expressed both PQBP-l and mutant ataxin-1 in
transgenic mouse brains. The interaction between these three proteins substantially
represses basal transcription.
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In another study, researchers investigated RNAPII function in Huntington’ s disease
(HD), a polyglutamine disease with many similar features to SCA3 (Luthi-Carter et al.,
2002). In HD transgenic mice, RNA polymerase II large subunit (RPIILS) protein levels
were decreased in cerebellum of mutant mice, whereas they were found to be increased
for RPIILS mRNA levels in the same brain region. However, RPIILS protein levels were
increased in striatum and cortex. Contrary to resuits in SCA1, RPIILS did co-localize
with huntingtin protein in the majority, but not ail, of the celis which contained nuclear
and cytoplasmic aggregates. However, it is unknown if sequestration ofRPIILS is
sufficient to influence transcription ofkey neuronal genes. It is also unknown if the
interaction is direct or through other transcriptional proteins that are sequestered.
Furthermore, even though it has been reported that sequestration of some transcription
factors could lead to the transcriptional suppression of specific genes, results in SCA1
and HD show that the presence of inclusion bodies is flot essential for repressing general
transcription (Hoshino et al., 2004). It is therefore more plausible that mutant proteins
disturb transcription by affecting nuclear factors in the nucleoplasm outside of inclusion
bodies (Hoshino et al., 2004).
Therefore, as RNAPII function does flot appear to be altered in SCA3, this illustrates that
transcriptional dysregulation as an underlying cause for cellular dysfunction does not
occur through the same mechanism for ail polyglutamine diseases. Transcriptionai
impairment is stili believed to be one of the causes of SCA3 pathogenicity, as several
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transcription factors have been implicated in this disease. Further investigation of
transcriptional dysregulation in SCA3 should consider other transcription factors
implicated in polyglutamine diseases, or look at splicing factors and mRNA processing
factors, as they also have dynamic relocalization pattems within the nucleus which are
dependent upon transcriptional activity ofthe celi (Zeng et al., 1997). Since
transcriptional impairment could be responsible for the degeneration observed in affected
fleurons, and since we have shown that in SCA3 this impairment seems to be independent
of RNAPII activity alterations, characterizing the mechanisms by which it might occur
would be important to understand the cellular pathology as well as to identify potential
therapeutic targets for SCA3 and other polyglutamine disorders.
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Chapter 5: General conclusion
5.1 Summary of this study
In the work presented here, we accomplished the following:
(1) We generated three full-length MJD1 constructs ofdifferent polyglutamine repeat
lengths and types, and tagged them in each reading frame.
(2) We characterized the expression ofthese constructs in Cos-l ceils to establish a
cellular model of SCA3.
(3) We also characterized a DrosophiÏa SCA3 model, previously established in our
laboratory, in order to use the model for ftirther experiments.
(4) We confirmed the occurrence ofribosomal frameshifling in our full-length SCA3
model.
(5) We investigated a mechanism oftranscriptional dysregulation in SCA3 using both
our cellular and Drosophila SCA3 models and concluded that transcriptional
impairment occurs independently of altered RNAPII function.
These resuits are relevant and important for several reasons. Firstly, developing a
cellular model of a human disease is important for the purpose of dissecting key features
ofthis pathology. Our cellular SCA3 model, together with models developed by others
in the field, is an essential tool to help understand aberrant processes leading to cellular
dysfunction, which cannot easily be studied otherwise. Furthermore, it has been shown
that each SCA3 model published so far lias unique features and adds to the knowledge of
the disease rnechanism in SCA3 and other expanded-CAG repeat disorders. The
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Drosophila SCA3 mode! we characterized will enable the in vivo study of disease
features and allow for the testing of other hypotheses, as we have done here.
Experiments using our fly model complemented our cellular model, as the basic
responses to cellular insuits are conserved between invertebrates and humans (Driscoli
and Gerstbrein, 2003); also, dissection ofthe mechanism oftoxicity in the fly will
provide better insight into the pathology of SCA3, as the in vivo model is one step doser
to human subjects. Overali, cellular and animal models will be most advantageous for
the identification of molecular targets and drug testing of emerging therapeutic strategies;
they can also be used in genetic screens for modifier genes and modulating phenotypes,
which can be used to prevent or improve clinical manifestations of the neurodegenerative
processes ofpolyglutamine disorders.
Secondly, confirming the occurrence ofribosomal ftameshifting using full-length MIDI
constructs in our SCA3 model provides sturdier support for the implication of
polyalanines in SCA3 disease progression. Ribosomal frameshifting is a nove! aspect of
polyglutamine disorders, whose consequences have harmful implications which extend
beyond SCA3, as this mechanism could also be present in numerous other CAG-repeat
disorders. Detailed investigation ofpolyglutamine and polyalanine toxicity in SCA3 will
lead to a better understanding of other proteinopathies caused by these proteins.
Lastly, several studies have shown that altered gene expression is implicated in the
pathology of many neurodegenerative disorders. As transcriptional dysfunction is one of
the earliest components ofpolyglutamine toxicity, understanding how it might occur
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would be most beneficial to the development oftherapies which could prevent any ofthe
initial pathological manifestations at the cellular level.
53 Opportunities for therapeutic intervention
Although much progress has been made in elucidating the molecular and cellular
mechanisms that underlie the pathology of SCA3 and other related disorders, effective
treatments have not yet been developed. Research on the development oftherapeutic
strategies is currently underway in several ofthe areas described below.
5.3.1 Misfolded protein
Targeting abnormal protein conformation by pharmacological means would be useful for
disease prevention as it would be applicable to ail polyglutamine diseases (Gusella and
MacDonald, 2000) and even polyalanine diseases, since they both involve misfolded
proteins. The use ofmouse and fly models has shown that many of the proteins invoived
in neurodegenerative diseases can take on misfolded conformations when mutated
(Zoghbi and Botas, 2002). Furthermore, protein misfolding underlies many unrelated
neurological diseases and therefore perturbations of its clearance might be a common
pathogenic event (Zoghbi and Botas, 2002).
5.3.2 CeIlular defense system
The cellular defense mechanism can be enhanced using drugs which activate chaperones
and stimulate proteasome activity selectively (Ross and Poirier, 2004). Chaperone
overexpression can confer protection by inhibiting signal transduction leading to ceil
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death, by suppressing stress kinases (Gabai et al., 1997), preventing caspase activation
(Zhou et al., 2001), or by coating misfolded proteins and preventing them from
interacting with other factors (Zoghbi and Botas, 2000). In fact, both Hsp7O and Hsp4O
were identified as modifiers of SCA3 and were shown to improve disease phenotypes in a
Drosophila model (Warrick et al., 199$).
5.3.3 Modulation of aggregation
As the debate over whether toxicity is mediated through the soluble or insoluble forms of
the mutant protein is still ongoing, it also remains unclear whether aggregates would be a
good target for therapies. Yet, the use of aggregation-inhibiting and promoting
compounds would be an alternative therapeutic target for these diseases (Gusella and
MacDonald, 2000). Chemical chaperones, synthetic peptides, intracellular antibodies and
certain chemicals, such as the azo-dye Congo red, can prevent oligomerization,
aggregation and also disintegrate existing aggregates, leading to significant improvement
of motor performance and extended lifespan (Michalik and Van Broeckhoven, 2003;
Sanchez et al., 2003). fi fact, inhibitors such as Congo red and cytamine were shown to
reduce aggregation by 33% and 66%, respectively, in a Huntington’s (HD) cellular
model. These compounds were further validated in a Drosophila model, in which rescue
of neuronal degeneration was demonstrated (Apostol et al., 2003). 0f interest to our
study is the use of cytamine, since it prevents aggregation through inhibition of
transglutaminase, an enzyme shown to be required for the formation ofpolymers in HD
(Kahlem et al., 1998). If indeed aggregation in SCA3 is dependent on transglutaminase
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activity, this drug could distinguish the effects of aggregates formed by glutamines versus
alanines.
Another method might be to target the nuclear iocalization signal ofthe affected proteins,
since they accumulate within the nucleus in SCA3. It lias been shown in SCA1 that when
the mutant protein is expressed in the cytoplasm rather than in the nucleus, neither
aggregation nor disease occurs (Kiement et al., 1998). These applications would be
important to many other neurodegenerative diseases such as Alzheimer’ s, amyotrophic
lateral scierosis and Parkinson’s disease, which also involve the graduai accumulation of
mutant proteins in the celi nucleus (Zoghbi and Off, 2000).
5.3.4 Mutant protein expression
The level of mutant protein can be reduced at the mRNA level through RNA interference
(Ross and Poirier, 2004). This effect lias been investigated in SCA3, where a small
interfering RNA (siRNA) was engineered to silence expression of the disease allele
which differed from wild-type alleles by a single nucleotide polymorphism (Miller et al.,
2003; Li et al., 2004).
5.3.5 Cleavage fragments
If in fact cleavage fragments are involved in SCA3 pathogenesis, decreasing their
concentration below a criticai level could be expiored as a goal for therapy (Goti et al.,
2004). This has been the case in Huntington’s disease, where inhibition ofthe caspase-1
enzyme prevented cleavage and led to recovery of the phenotype (Ona et al., 1999).
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5.3.6 Apoptotic inhibitors
The successful use ofother caspase inhibitors such as zVAD-ffiik and minocycline, used
to prevent the activation ofthe apoptotic pathway in HD models (Ona et al., 1999), could
be applicable to other polyglutamine diseases. Also important to the study of apoptotic
inhibitors is the effect of contagious apoptosis, whereby neighbouring celis are exposed
to triggering factors that are similar to those that affect a ceil that is dying, as the dying
neuron releases proapototic factors (friediander, 2003). Using inhibitors of apoptosis
wilI flot only slow the death of one particular celi, but also restrict the production of
diffusible toxic factors. This would be important in controlling the number of neuronal
ceils affected by apoptosis.
5.3.7 Transcriptional dysregulation
Given that the transcriptional machinery is impaired in many polyglutamine disorders,
one possibility for treatment would be through administration of histone deacetylase
inhibitors, such as suberoylanilide hydroxamic acid (SAHA). This chemical has been
shown to be effective in Drosophila and mouse models of Huntington’ s as it dramatically
improved the motor impairment oftransgenic mice (Hockly et al., 2003). Another
example was done using genetic reduction ofSin3A corepressor activity in a Drosophila
mode! which alleviated transcriptional repression (Steffan et al., 2001). Though RNAPII
function was flot impaired in SCA3 (as shown by our resuits), other polyglutamine
disorders could benefit from the use ofdrugs, such as 5,6-dichloro-1-[beta]-D-
ribofuranosylbenzimidazole (DRB) or isoquinolinesulfonamide derivatives (H8 and H7)
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(Dubois et al., 1994), which modulate phosphorylation levels ofRNAPII and could be an
effective therapy for this type of transcriptional dysregulation.
5.4 Conclusion
The research presented in this manuscript along with ail other findings published in the
field, contribute to a better understanding ofMachado-Joseph disease (SCA3).
Hopefully, this work wiYl be applicable to finding a cure for flot only this disorder, but
also for other related diseases with the ultimate goal ofimproving a patient’s quality of
life.
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